Combination therapy methods for the treatment of prostate cancer with

By adjusting the dosing schedule of anti-androgen compounds and PSMA-targeted T cell conjugates, the problems of drug resistance and side effects in prostate cancer treatment were solved, the safety and tolerance of treatment were improved, and metastasis was achieved Effective control of sexual castration-resistant prostate cancer.

CN118946583APending Publication Date: 2024-11-12AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028616.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-21
Filing Date
2023-03-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing prostate cancer treatment methods, especially for metastatic castration-resistant prostate cancer, have drug resistance problems and side effects, and the safety and tolerance of combination therapy are insufficient, making it difficult to effectively control disease progression in the long run.

Method used

By determining the combined dosing schedule of anti-androgen compounds with PSMA-targeted T cell conjugates, delaying the onset of treatment of anti-androgen compounds to reduce serious adverse events and dose-limiting toxicity, improving the safety of combination therapy and Tolerability while maintaining anti-tumor efficacy.

Benefits of technology

It significantly reduced the number and dose-limiting toxicity of serious adverse events in combination therapy, maintained anti-tumor efficacy, improved the safety and tolerance of treatment, and extended the effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005049475080000391
    Figure BDA0005049475080000391
  • Figure BDA0005049475080000401
    Figure BDA0005049475080000401
  • Figure BDA0005049475080000402
    Figure BDA0005049475080000402
Patent Text Reader

Abstract

The present invention relates to methods of treating prostate cancer using a combination of an anti-androgen compound and a T cell conjugating molecule that specifically binds to human prostate specific membrane antigen (PSMA) and human CD3. In particular, the present invention relates to methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, in a patient in need thereof, comprising administering to the patient one or more cycles of an antiandrogen compound and a PSMA-targeting T-cell conjugating molecule in combination, wherein the administration of a first dose of the anti-androgen compound is delayed relative to the administration of a first therapeutic dose of the PSMA-targeting T cell conjugating molecule in a first cycle.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 322,138, filed on March 21, 2022, which is hereby incorporated by reference in its entirety.

[0003] Instructions for electronically submitting text files

[0004] This application contains a sequence listing that has been submitted electronically in XML format, and the sequence listing is hereby incorporated by reference in its entirety. A computer-readable format copy of the sequence listing created on March 20, 2023 is named 10004-WO01-SEC_ST26.xml and is 206,177 bytes in size. Technical Field

[0005] The present invention relates to the fields of immuno-oncology and biopharmaceuticals. In particular, the present invention relates to methods for treating prostate cancer, especially castration-resistant prostate cancer, by administering a T cell engagement molecule that specifically binds to human prostate-specific membrane antigen (PSMA) and human cluster of differentiation 3 (CD3) in combination with an anti-androgen compound according to a specific dosing schedule. Background Art

[0006] Prostate cancer is the second most common malignancy diagnosed in men worldwide (after lung cancer). In 2018, a total of 1,276,106 new cases of prostate cancer were reported worldwide, and prostate cancer caused 358,989 deaths (accounting for 3.8% of total cancer deaths in men) (Rawla, World J Oncol., Vol. 10: 63-89, 2019).

[0007] Metastasis is the main cause of morbidity and mortality of prostate cancer. Since 1941, patients diagnosed with metastatic prostate cancer have been receiving continuous androgen deprivation therapy (ADT), in the form of surgical castration, chemical castration involving luteinizing hormone-releasing hormone agonist (LHRH) regulatory compounds, and / or anti-androgen therapy. Metastatic prostate cancer is usually resistant to ADT ("castration resistance") (Galletti et al., Cancer Treat Rev. [Cancer Therapy Review], Vol. 57: 16-27, 2017) due to increased intratumoral steroid production, altered steroid transporter expression, increased androgen receptor expression (such as androgen receptor amplification) and other mechanisms. Since 2010, several therapies have been approved for the treatment of these patients with metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide and abiraterone, two novel hormone therapies, have shown significant survival benefits in mCRPC patients. In first-line mCRPC, abiraterone plus prednisone increased the median OS from 30.3 months to 34.7 months compared with placebo plus prednisone. Similarly, enzalutamide increased OS in the first-line mCRPC environment (35.3 months vs. 31.3 months) (Sartor and de Bono, N Engl J Med. [New England Journal of Medicine], Vol. 378: 645-657, 2018). Radium-223 also showed a survival benefit in patients with bone metastases when combined with the best standard of care including old-fashioned hormone therapy, radiation, and bisphosphonates (14.9 months vs. 11.3 months). Compared with placebo, autologous cell immunotherapy Sipuleucel-T increased the median survival by 4.1 months, but no PSA and radiographic responses were observed. Compared with mitoxantrone, cabazitaxel (Cabazitaxel, a tubulin-binding taxane) increased the median survival by 2.4 months, but many trial participants did not complete treatment due to toxicity. Although recently approved therapies have shown survival benefits for patients with mCRPC, drug resistance often complicates the disease process and leads to relapse and death. In addition, the effects of approved therapies are often not durable and may be associated with limited tolerance. See, for example, de Bono et al., Lancet, Vol. 376: 1147-54, 2010; Scher et al., N Engl J Med, Vol. 367: 1187-97, 2012; Parker et al., N Engl J Med, Vol. 369: 213-23, 2013; and Ryan et al., Lancet Oncol, Vol. 16: 152-60, 2015.

[0008] Emerging PSMA-targeted therapies have shown activity in patients with mCRPC (Hofman et al., Lancet Oncol., Vol. 19(6):825-833, 2018). PSMA is a 100 kDa type II integral membrane glycoprotein that is primarily expressed on prostate epithelial cells (Christiansen et al., Prostate, Vol. 55:9-19, 2003; Israeli et al., Cancer Res., Vol. 53:227-230, 1993). PSMA is expressed in the prostate and in a limited number of tissues, including a subset of renal proximal tubules, some cells of the intestinal brush border membrane, liver, and rare cells in the crypts of the colon (O'Keefe et al., Prostate, 58:200-210, 2004; Chang et al., Cancer Res., 59:3192-3198, 1999; Troyer et al., Int J Cancer, 62:552-558, 1995; Israeli et al., Cancer Res., 54:1807-1811, 1994; Lopes et al., Cancer Res., 50:6423-6429, 1990; Horoszewicz et al., Anticancer Research, 51:6423-6429, 1990). Res. [Anticancer Research], Vol. 7: 927-935, 1987). In prostate cancer, expression of PSMA increases with disease progression and is highest in metastatic disease, hormone-refractory cases, and high-grade lesions. There is a strong correlation between poor prognosis and cell surface expression of PSMA. Consistent with the correlation between PSMA expression and tumor stage, elevated PSMA levels are associated with androgen-independent prostate cancer (Wright et al., Urology [Urology], Vol. 48: 326-334, 1996; Israeli et al., 1994, supra). Immunohistochemical analysis shows that compared with benign prostate tissue, the expression of PSMA in metastatic lesions located in lymph nodes, bones, soft tissues and lungs is relatively strong and uniform (Chang et al., Urology, Vol. 57: 1179-1183, 2001; Sweat et al., Urology, Vol. 52: 637-640, 1998; Murphy et al., Cancer, Vol. 78: 809-818, 1996). The restricted expression of PSMA and its upregulation in advanced cancers and metastatic disease make PSMA an attractive target for the development of prostate cancer therapies.

[0009] Advanced prostate cancer is a heterogeneous disease that often develops resistance to single-agent therapy (Carm et al., Sci Rep. [Scientific Reports], Vol. 9: 13579, 2019). Therefore, combination therapy is needed to overcome disease heterogeneity and resistance to therapy. It is reported that anti-androgen therapy (such as enzalutamide and abiraterone) upregulates the expression of PSMA on prostate cancer cells (see, for example, Deegen et al., Clin. Cancer Res. [Clinical Cancer Research], Vol. 27: 2928-2937, 2021; Aggarwal et al., Eur. Urol. Oncol. [European Journal of Urological Oncology], Vol. 1: 78-82, 2018; Emmett et al., J Nucl. Med. [Journal of Nuclear Medicine], Vol. 60: 950-954, 2019). PSMA-targeted T cell engagers are a new class of immunotherapy that engages the patient's own T cells and redirects them to kill PSMA-expressing cancer cells. Combination therapy of anti-androgen compounds that upregulate PSMA expression on cancer cells with PSMA-targeted T cell engagers can provide a synergistic anti-tumor effect. In fact, in vitro experiments have shown that enzalutamide enhances the cytotoxicity of prostate cancer cells induced by PSMA-targeted T cell engagers (Deegen et al., 2021, supra). However, the side effects associated with this combination therapy in human patients are unclear. Therefore, there is a need in the art for safe and effective methods to administer anti-androgen compounds in combination with PSMA-targeted immunotherapy to treat prostate cancer, particularly mCRPC. Summary of the invention

[0010] The present invention is based in part on the identification of dosing schedules for anti-androgen compounds in combination with PSMA-targeted T cell engagers that improve the safety and tolerability of the combination therapy while maintaining optimal anti-tumor efficacy. Thus, in one embodiment, the present invention provides a method of treating prostate cancer in a patient in need thereof, the method comprising administering to the patient one or more cycles of an anti-androgen compound in combination with a T cell engager that specifically binds to human PSMA and human CD3, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engager.

[0011] In certain embodiments, the first cycle (also referred to herein as the initiation cycle) comprises administering the first dose of the anti-androgen compound about 4 days to about 10 days or about 5 days to about 9 days after the administration of the first therapeutic dose of the PSMA-targeted T cell engaging molecule. For example, in some embodiments, the first cycle comprises administering the first dose of the anti-androgen compound about 5 days, about 6 days, or about 7 days after the administration of the first therapeutic dose of the PSMA-targeted T cell engaging molecule.

[0012] In some embodiments of the methods of the invention, the first cycle further comprises administering to the patient one or more priming doses of the T cell engager molecule prior to administering the first therapeutic dose of the T cell engager molecule. In some embodiments, such priming doses may be lower than the therapeutic dose of the T cell engager molecule, but sufficient to induce T cell activation in the patient, thereby priming or preparing the patient for a higher dose of the T cell engager molecule, such that administration of the higher dose results in a reduced number or severity of adverse events such as cytokine release syndrome. In some embodiments in which one or more priming doses of the PSMA-targeted T cell engager molecule are administered to the patient in the first cycle, the first therapeutic dose of the T cell engager molecule may be administered about 1 day to about 21 days, about 1 day to about 14 days, or about 1 day to about 7 days after the first priming dose of the PSMA-targeted T cell engager molecule is administered to the patient. In certain embodiments, the first therapeutic dose of the PSMA-targeted T cell engager molecule is administered about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days after the first priming dose of the PSMA-targeted T cell engager molecule is administered.

[0013] In various embodiments of the methods of the present invention, the PSMA-targeted T cell engaging molecule is administered to the patient by intravenous infusion or subcutaneous injection. In some embodiments, one or more doses of the PSMA-targeted T cell engaging molecule are administered to the patient by continuous intravenous infusion over an extended period of time (such as over a period of 1 to 7 days). In some embodiments, one or more doses of the PSMA-targeted T cell engaging molecule are administered to the patient by intravenous push (also referred to herein as short intravenous infusion) over a period of about 30 minutes to about 90 minutes. In certain embodiments, the first dose of the PSMA-targeted T cell engaging molecule in the first cycle is administered by continuous intravenous infusion over a period of 1 to 7 days, for example, over a period of 3 days (i.e., a 72-hour infusion period). In some such embodiments, the first dose may be a pre-excitation dose and is less than the amount of the therapeutic dose. In a related embodiment, one or more therapeutic doses of the PSMA-targeted T cell engaging molecule may then be administered to the patient by intravenous push in the first cycle.

[0014] In some embodiments, the anti-androgen compound is orally administered to the patient. Depending on the anti-androgen compound used, the anti-androgen compound is administered to the patient once a day, twice a day, or three times a day in the form of an oral dosage form (such as a tablet or capsule). The anti-androgen compound can be abiraterone, abiraterone acetate, ketoconazole, flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, or darolutamide. In certain embodiments, the anti-androgen compound administered to the patient according to the method of the present invention is enzalutamide, abiraterone, abiraterone acetate, apalutamide, or darolutamide. In one embodiment, the anti-androgen compound is enzalutamide. Enzalutamide can be orally administered to the patient once a day at a dose of about 160 mg. In another embodiment, the anti-androgen compound is abiraterone or abiraterone acetate. In some such embodiments, abiraterone or abiraterone acetate is orally administered to the patient once a day at a dose of about 1,000 mg. In yet another embodiment, the anti-androgen compound is apalutamide, which can be orally administered to the patient at a dose of about 240 mg once a day. In yet another embodiment, the anti-androgen compound is darolutamide. In some embodiments, darolutamide is orally administered to the patient at a dose of about 600 mg twice a day.

[0015] The first cycle may have a duration of about 14 days to about 56 days or about 21 days to about 28 days. In certain embodiments of the methods of the present invention, the first cycle has a duration of about 28 days. In such embodiments, the first cycle may include administering PSMA-targeted T cell engagement molecules on days 1, 8, 15, and 22 of the cycle, and administering anti-androgen compounds once a day on each of days 15 to 28 of the cycle. In other embodiments, the first cycle may include administering PSMA-targeted T cell engagement molecules on days 1 and 15 of the cycle, and administering anti-androgen compounds once a day on each of days 15 to 28 of the cycle. In certain other embodiments where the first cycle is about 28 days, the first cycle may include administering a first dose (e.g., a pre-stimulation dose) of PSMA-targeted T cell engagement molecules by continuous intravenous infusion on days 1 to 3 of the cycle, administering a therapeutic dose of the PSMA-targeted T cell engagement molecules by intravenous push on days 8 and 22 of the cycle, and administering anti-androgen compounds orally once a day on each of days 15 to 28 of the cycle. In such embodiments, the first dose (e.g., priming dose) of the PSMA-targeted T cell engaging molecule can be about 30 μg to about 300 μg or about 30 μg to about 150 μg, and the therapeutic dose of the PSMA-targeted T cell engaging molecule can be about 90 μg to about 1.8 mg or about 100 μg to about 600 μg. In a specific embodiment, the first dose (e.g., priming dose) of the PSMA-targeted T cell engaging molecule is about 90 μg and the therapeutic dose is about 150 μg or 300 μg.

[0016] In some embodiments, the methods further include administering to the patient one or more maintenance cycles of anti-androgen compounds and PSMA-targeted T cell engaging molecules in combination. In one embodiment, the maintenance cycle includes oral administration of the anti-androgen compound once a day on each day of the cycle, and administering a therapeutic dose of the PSMA-targeted T cell engaging molecule by intravenous injection once every 7 days or once every 14 days. The duration of the maintenance cycle can be about 21 days to about 42 days, about 28 days to about 56 days, or about 21 days to about 28 days. In certain embodiments, the maintenance cycle has a duration of about 28 days. The maintenance cycle can be administered on the second day after the first cycle is completed, for example, there is no treatment-free period between the first cycle and the maintenance cycle. In other embodiments, the maintenance cycle is administered about 7 days after the first cycle is completed-that is, there is a 7-day treatment-free period between the first cycle and the maintenance cycle. Patients can receive multiple maintenance cycles, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or more maintenance cycles. In some embodiments, a maintenance cycle is administered to the patient until the patient responds to the treatment, eg, achieves a complete response.

[0017] In certain embodiments, the prostate cancer treated according to the method of the present invention is metastatic prostate cancer. Therefore, the patient treated according to the method of the present invention suffers from or is diagnosed with metastatic prostate cancer. Metastatic prostate cancer can be hormone-sensitive, or it can be resistant to hormone therapy. Therefore, in one embodiment, the patient treated according to the method of the present invention suffers from or is diagnosed with metastatic castration-resistant prostate cancer.

[0018] The prostate cancer patient to be treated according to the method of the present invention may have received one or more previous therapies for prostate cancer and has failed or become intolerant, refractory or resistant to one or more of these previous therapies. For example, in some embodiments, these patients have failed or are intolerant, refractory or resistant to one or more chemotherapy regimens (such as chemotherapy regimens containing taxanes). Additionally or alternatively, these patients have failed or are intolerant, refractory or resistant to one or more anti-androgen compounds (such as abiraterone, enzalutamide, apalutamide or darolutamide). In such embodiments, the anti-androgen compound to be administered to the patient in combination with the PSMA-targeted T cell engaging molecule according to the method of the present invention is preferably an anti-androgen compound different from the anti-androgen compound previously received by the patient. In certain embodiments, the patient to be treated according to the method of the present invention has been treated with radioligand therapy (such as 177 Lu-PSMA-617) failed or was intolerant, refractory, or resistant.

[0019] In any embodiment of the methods disclosed herein, the PSMA-targeted T cell engaging molecule administered to the patient specifically binds to PSMA and CD3, preferably human PSMA and human CD3. Thus, the PSMA-targeted T cell engaging molecule comprises a first domain that specifically binds to human PSMA and a second domain that specifically binds to human CD3. The binding domain may comprise structural elements from an antibody or an antigen-binding fragment thereof, such as a heavy chain variable region and a light chain variable region. In one embodiment, any one or both of the binding domains of the PSMA-targeted T cell engaging molecule used in the methods of the present invention is a single chain variable fragment (scFv). In some embodiments of the methods described herein, the PSMA-targeted T cell engaging molecules further comprise an Fc domain having one or more immunoglobulin Fc monomers. In such embodiments, the Fc domain may be a single chain Fc domain.

[0020] In certain embodiments, the PSMA-targeted T cell engaging molecule administered to a patient according to the methods of the present invention comprises, in order from amino to carboxyl: (i) a first domain that specifically binds to human PSMA, (ii) a second domain that specifically binds to human CD3, and (iii) an Fc domain comprising two Fc monomers, each monomer comprising an immunoglobulin hinge region, a CH2 domain, and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker. In one embodiment, the first domain comprises a first immunoglobulin heavy chain variable region (VH1) and a first immunoglobulin light chain variable region (VL1), the VH1 comprising a CDRH1 having a sequence of SEQ ID NO: 14, a CDRH2 having a sequence of SEQ ID NO: 16, and a CDRH3 having a sequence of SEQ ID NO: 20, the VL1 comprising a CDRL1 having a sequence of SEQ ID NO: 5, a CDRL2 having a sequence of SEQ ID NO: 8, and a CDRL3 having a sequence of SEQ ID NO: 9. In related embodiments, the second domain comprises a second immunoglobulin heavy chain variable region (VH2) comprising a CDRH1 having a sequence of SEQ ID NO: 49, a CDRH2 having a sequence of SEQ ID NO: 55, and a CDRH3 having a sequence of SEQ ID NO: 60, and a second immunoglobulin light chain variable region (VL2), the VH2 comprising a CDRH1 having a sequence of SEQ ID NO: 49, a CDRH2 having a sequence of SEQ ID NO: 55, and a CDRH3 having a sequence of SEQ ID NO: 60, the VL2 comprising a CDRL1 having a sequence of SEQ ID NO: 43, a CDRL2 having a sequence of SEQ ID NO: 44, and a CDRL3 having a sequence of SEQ ID NO: 47. In some embodiments, the first domain of the PSMA-targeted T cell engaging molecule (e.g., an anti-PSMA domain) comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 33 and a light chain variable region comprising a sequence of SEQ ID NO: 30. In these and other embodiments, the second domain of the PSMA-targeted T cell engager molecule (e.g., an anti-CD3 domain) comprises a heavy chain variable region comprising the sequence of SEQ ID NO:72 and a light chain variable region comprising the sequence of SEQ ID NO:70.

[0021] The PSMA-targeted T cell engaging molecule administered to a patient according to the methods of the present invention comprises: (i) a first domain that specifically binds to human PSMA and has an amino acid sequence of SEQ ID NO: 104, (ii) a second domain that specifically binds to human CD3 and has an amino acid sequence of SEQ ID NO: 116, and (iii) an Fc domain comprising two Fc monomers each having an amino acid sequence of SEQ ID NO: 124, wherein the two Fc monomers are fused to each other via a peptide linker. In a related embodiment, the Fc domain of the PSMA-targeted T cell engaging molecule comprises an amino acid sequence of SEQ ID NO: 132. In certain embodiments, the PSMA-targeted T cell engaging molecule used in the methods of the present invention is a single-chain polypeptide or a single-chain fusion protein. Therefore, any single-chain polypeptide described in Table 6 herein is suitable for use in the methods of the present invention. In a preferred embodiment, the PSMA-targeted T cell engaging molecule administered to a patient according to the methods of the present invention is a single-chain polypeptide (e.g., acapatamab) comprising an amino acid sequence of SEQ ID NO: 140.

[0022] The present invention also provides pharmaceutical compositions of PSMA-targeted T cell engaging molecules used in combination with anti-androgen compounds in the methods described herein. These pharmaceutical compositions may include one or more pharmaceutically acceptable diluents, carriers or excipients, including buffers, surfactants and stabilizers. In certain embodiments, these pharmaceutical compositions include PSMA-targeted T cell engaging molecules, buffers, surfactants and stabilizers. In one embodiment, these pharmaceutical compositions include PSMA-targeted T cell engaging molecules (e.g., single-chain polypeptides comprising the amino acid sequence of SEQ ID NO: 140) at a pH of about 4.0 to about 4.4, glutamate buffers, polysorbate 20 or polysorbate 80, and sucrose. In some embodiments, these pharmaceutical compositions can be lyophilized and reconstituted before administration to a patient.

[0023] The use of a PSMA-targeted T cell engager in combination with an anti-androgen compound in any of the methods disclosed herein or for the preparation of a medicament for administration according to any of the methods disclosed herein is specifically contemplated. For example, the present invention includes a PSMA-targeted T cell engager in combination with an anti-androgen compound in a method for treating prostate cancer in a patient in need thereof, wherein the method comprises administering a first cycle of the PSMA-targeted T cell engager and the anti-androgen compound, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engager. The present invention also includes the use of a PSMA-targeted T cell engager for the manufacture of a medicament for treating prostate cancer in a patient in need thereof, wherein the treatment comprises administering to the patient a first cycle of the PSMA-targeted T cell engager and the anti-androgen compound, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engager. DETAILED DESCRIPTION

[0024] The present invention is based in part on the following findings: Delaying the start of treatment with an anti-androgen compound for an extended period of time after the administration of the PSMA-targeted T cell engagement molecule significantly reduces the number of serious adverse events and dose-limiting toxicities observed in the combination therapy, compared to the regimen in which the PSMA-targeted T cell engagement molecule and the anti-androgen compound are first administered to the patient simultaneously. See Example 1. In addition, the anti-tumor efficacy of the combination is comparable between the two regimens. These results are surprising to some extent for at least two reasons. Based on the mechanism of action of anti-androgen compounds and PSMA-targeted T cell engagement molecules, it is not expected that toxicity overlap will occur because the potential adverse events of each molecule are different. For example, the most common adverse events of anti-androgen compounds (such as enzalutamide) are hot flashes and fatigue, while the most common adverse event of PSMA-targeted T cell engagement molecules is cytokine release syndrome (CRS). Secondly, it has been reported that anti-androgen compounds upregulate the expression of PSMA on prostate cancer cells, suggesting that anti-androgen compounds should be administered before or at least simultaneously with PSMA-targeted T cell engagement molecules to observe synergistic effects on the cytotoxicity of tumor cells. However, delaying the start of treatment with an anti-androgen compound did not significantly affect the efficacy of the combination therapy (see Example 1). Therefore, the present invention provides methods for administering an anti-androgen compound in combination with a PSMA-targeted T cell engager that improves the safety and tolerability of the combination therapy while maintaining optimal anti-tumor efficacy in patients with prostate cancer. Therefore, in certain embodiments, the present invention provides methods for treating prostate cancer in patients in need thereof, comprising administering to the patient one or more cycles of an anti-androgen compound and a T cell engager that specifically binds to human PSMA and human CD3, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engager.

[0025] Prostate cancer is one of the most common types of cancer in men and occurs when cells in the prostate begin to grow out of control. Most forms of prostate cancer are adenocarcinomas, which are tumors formed by glandular cells. Other forms of prostate cancer include small cell carcinomas, neuroendocrine tumors, transitional cell carcinomas, and sarcomas. Prostate cancer is initially confined to the prostate, but can metastasize and spread to other tissues. Metastatic prostate cancer can be divided into two main types: the first type ("metastatic hormone-sensitive prostate cancer" or mHSPC) in which the cancer has not been treated with androgen deprivation therapy, and the second type ("metastatic castration-resistant prostate cancer" or mCRPC) in which the cancer is resistant to androgen deprivation therapy. In prostate cancer, the expression of PSMA increases as the disease progresses and is highest in metastatic disease, hormone-refractory cases, and high-grade lesions.

[0026] Prostate cancer may not cause any signs or symptoms in its early stages. Along with disease progression, the signs and symptoms of prostate cancer may include incontinence, dysuria, blood in semen or urine, erectile dysfunction, pelvic region or bone pain, or weakness in legs and feet. Typically, one or more tests are carried out to diagnose and monitor prostate cancer by samples (such as blood, serum, plasma, semen, tissue) from a subject or patient suspected of suffering from or developing into prostate cancer. Sample can be any biological sample obtained from a human patient, and can include body fluids (such as blood, serum, plasma, semen and urine) and tissues (such as prostate tissue, lymph nodes or tumor biopsies). Common tests for screening and / or monitoring prostate cancer are prostate specific antigen (PSA) blood tests. The rise of PSA in blood (such as serum or plasma) can be used as an indicator of prostate cancer existence or development. Another test commonly used in detecting or monitoring prostate cancer is prostate tissue biopsy. The presence of abnormal cells or cancerous cells in the prostate tissue biopsy sample is evaluated. If cancerous cells are present, the prostate cancer may be graded according to the Gleason score system, or other grading systems, which are based on how abnormal the cells appear compared to normal cells. The Gleason score can range from 2 (non-aggressive cancer) to 10 (very aggressive cancer). Prostate cancer may also be diagnosed or monitored using imaging tests, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), the use of radioactive tracers such as 68 Gallium-PSMA-11, Piflustat F-18 (also known as 18 F-DCFPyL) or 18 F-fluorodeoxyglucose) or bone scan (e.g., using 98m Bone scintigraphy with a technetium-labeled radioactive tracer).

[0027] In certain embodiments, the patient to be treated according to the methods of the present invention has or has been diagnosed with prostate cancer. In such embodiments, the prostate cancer is PSMA positive—that is, the tumor or cancer cell expresses PSMA, as determined by standard immunohistochemistry testing of biopsy samples or PSMA imaging methods. In some embodiments, the patient to be treated according to the methods of the present invention has a blood PSA level of 4ng / mL or more. In other embodiments, the patient to be treated according to the methods of the present invention has a blood PSA level of 10ng / mL or more. In still other embodiments, the patient to be treated according to the methods of the present invention has a blood PSA level of 1ng / mL or more, wherein the PSA level rises on at least two consecutive occasions at least one week apart. In some embodiments, the patient to be treated according to the methods of the present invention has a prostate cancer with a Gleason score of 7. In other embodiments, the patient to be treated according to the methods of the present invention has a prostate cancer with a Gleason score of 8. In yet other embodiments, the patient to be treated according to the methods of the present invention has a prostate cancer with a Gleason score of 9 or 10. In some embodiments, the patient to be treated according to the methods of the present invention may have just been diagnosed with prostate cancer. Some patients in need of treatment may have been diagnosed with hormone-sensitive prostate cancer or castration-resistant prostate cancer.

[0028] In certain embodiments, the patient treated according to the method of the present invention suffers from or is diagnosed with metastatic prostate cancer. Metastatic prostate cancer can be hormone-sensitive or resistant to hormone therapy. The patient diagnosed with metastatic prostate cancer has evidence of cancerous prostate cells outside the prostate, such as in lymph nodes, bones or other organs, most commonly liver, lungs or brain. Typically, one or more of the above-mentioned imaging methods (such as CT, MRI, PET or bone scans) are used to detect the evidence of cancer cell spread by the presence of tumors or lesions in other tissues. In certain embodiments, the patient treated according to the method of the present invention has evidence of progressive prostate cancer, showing the progress of lymph nodes or visceral tumors, as defined by the solid tumor response evaluation criteria (RECIST) 1.1 optionally modified with prostate cancer working group 3 (PCWG3) (see Eisenhauer et al., European Journal of Cancer [European Journal of Cancer], Vol. 45: 228-247, 2009; Scher et al., J.Clin, Oncol [Clinical Oncology Journal], Vol. 34: 1402-1418, 2016). In other embodiments, patients to be treated according to the methods of the present invention have evidence of progressive prostate cancer as evidenced by the presence of two or more new bone lesions, as determined by bone scanning (e.g., using 98m Determined by bone scintigraphy using a technetium-labeled radioactive tracer.

[0029] In certain embodiments, the patient treated according to the method of the present invention suffers from or is diagnosed with metastatic castration-resistant prostate cancer (mCRPC). When cancer progresses in patients with metastatic disease, mCRPC is diagnosed, even if the patient's testosterone level is equal to or lower than the testosterone level achieved by androgen deprivation therapy. In certain embodiments, patients diagnosed with mCRPC may have failed, become refractory or relapsed after being treated with androgen deprivation therapy. Androgen deprivation therapy includes surgical castration (e.g., bilateral orchiectomy), chemical castration with LHRH agonists or antagonists (e.g., leuprolide, goserelin, triptorelin, histrelin, relugolix or degarelix) or treatment with anti-androgen compounds (such as androgen biosynthesis inhibitors (e.g., abiraterone, ketoconazole) or androgen receptor antagonists (e.g., flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide or darolutamide)). In some embodiments, the patient to be treated according to the methods of the present invention has a total serum testosterone level of 50 ng / dL (1.7 nmol / L) or less. In other embodiments, the patient to be treated according to the methods of the present invention has a total serum testosterone level of 20 ng / dL (0.7 nmol / L) or less. In certain embodiments, the patient to be treated according to the methods of the present invention has undergone bilateral orchiectomy. In other embodiments, the patient to be treated according to the methods of the present invention is receiving a continuous treatment regimen of an LHRH agonist or antagonist. In yet other embodiments, the patient to be treated according to the methods of the present invention has undergone bilateral orchiectomy and is receiving a continuous treatment regimen of an LHRH agonist or antagonist.

[0030] Androgen receptor (AR) signaling changes in patients with castration-resistant prostate cancer (CRPC), and therefore, patient tumors develop various mutations in genes encoding proteins in the androgen receptor signaling pathway (see Sartor and de Bono, NEngl J Med. [New England Journal of Medicine], Vol. 378: 645-657, 2018). Such mutations include mutations in AR, FOXA1, ZBTB16, and SPOP genes, as well as mutations in genes (such as PTEN, ET5, BRCA2, ATM, and CHEK2) involved in AKT signaling, DNA repair, and tumor suppression. Therefore, the diagnosis of CRPC or mCRPC can be supplemented by gene expression profiling or genotyping to confirm the initial diagnosis and / or identify the subtype of CRPC or mCRPC.

[0031] The PSMA-targeted T cell engaging molecule is administered in combination with an anti-androgen compound according to the methods of the present invention for the purpose of treating prostate cancer or other PSMA-expressing cancers or tumors. As used herein, the term "treatment" or "treat" refers to the application or administration of a T cell engaging molecule in combination with an anti-androgen compound to a patient who has or has been diagnosed with prostate cancer or other PSMA-positive malignancies; a patient who has symptoms of prostate cancer or other PSMA-positive malignancies; a patient who is at risk of developing prostate cancer or other PSMA-positive malignancies; or a patient who is susceptible to prostate cancer or other PSMA-positive malignancies for the purpose of treating, curing, alleviating, relieving, altering, improving or ameliorating prostate cancer or other PSMA-positive malignancies, one or more symptoms of prostate cancer or other PSMA-positive malignancies, risk of developing prostate cancer or other PSMA-positive malignancies, or susceptibility to prostate cancer or other PSMA-positive malignancies. The term "treatment" encompasses any improvement of a patient's disease, including slowing or stopping the progression of a patient's prostate cancer or other PSMA-positive malignancies, reducing the number or severity of symptoms of prostate cancer or other PSMA-positive malignancies, or increasing the frequency or duration of a patient being free of symptoms of prostate cancer or other PSMA-positive malignancies. The term "patient" includes human patients.

[0032] In certain embodiments of the methods of the invention, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound reduces the blood level (e.g., serum or plasma level) of PSA in a patient relative to the blood level of PSA in the patient before the start of treatment (i.e., before the administration of the PSMA-targeted T cell engaging molecule and the anti-androgen compound) by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%, or about 100%. In some embodiments, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound reduces the blood level of PSA in the patient by 30% or more relative to the blood level of PSA in the patient before the start of treatment (i.e., a PSA30 response). In other embodiments, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound reduces the blood level of PSA in the patient by 50% or more relative to the blood level of PSA in the patient before the start of treatment (i.e., a PSA50 response). In yet other embodiments, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound reduces the PSA blood level in the patient by 70% or more relative to the PSA blood level in the patient before the start of treatment (i.e., a PSA70 response). In still other embodiments, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound reduces the PSA blood level in the patient by 90% or more relative to the PSA blood level in the patient before the start of treatment (i.e., a PSA90 response). In certain embodiments of the methods of the invention, the administration of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound produces a PSA50 response in at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of prostate cancer patients.

[0033] In some embodiments of the methods of the invention, administration of a PSMA-targeted T cell engager molecule in combination with an anti-androgen compound induces a complete response, a partial response, or a stable disease response in at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of prostate cancer patients with measurable tumors or lesions prior to the start of treatment as determined by RECIST 1.1 criteria, optionally with PCWG3 modifications (see Eisenhauer et al., European Journal of Cancer, Vol. 45:228-247, 2009; Scher et al., J. Clin, Oncol, Vol. 34:1402-1418, 2016). In the context of the present invention, a complete response (CR) refers to a condition in which all target lesions have disappeared (i.e., are no longer detectable) and any pathological lymph nodes have shrunk to less than 10 mm in the short axis. A partial response (PR) refers to a condition in which the sum of the diameters of the target lesions has shrunk by at least 30% relative to the sum of the diameters before the start of treatment. Stable disease (SD) refers to a condition in which the target lesions have not shrunk enough to be assessed as a PR but have not increased enough to be assessed as progressive disease (PD). PD refers to a condition in which one or more new target lesions appear or the sum of the diameters of the target lesions has increased by at least 20% relative to the sum of the smallest diameters that have appeared previously and the absolute value of the sum of the diameters has increased to at least 5 mm.

[0034] The efficacy of the treatment regimens described herein can also be assessed based on the reduction in PSMA-positive tumor burden relative to the PSMA-positive tumor burden before the start of treatment, as measured by 68 Ga-PSMA-11 PET / CT imaging, pyrifos F-18 ( 18 F-DCFPyL) PET / CT imaging or imaging with other PSMA radiographic PET tracers; the percentage of patients achieving a circulating tumor cell (CTC) response; the duration of response to treatment; the time to disease progression; progression-free survival (PFS); and overall survival (OS). In certain embodiments, the duration of response to treatment, the time to disease progression, PFS, and / or OS observed in a standard chemotherapy regimen (e.g., a taxane chemotherapy regimen) or a standard androgen deprivation therapy regimen are compared to the duration of response to treatment, the time to disease progression, PFS, and / or OS observed in a standard chemotherapy regimen (e.g., a taxane chemotherapy regimen) or a standard androgen deprivation therapy regimen. The combination of a PSMA-targeted T cell engagement molecule and an anti-androgen compound according to the methods of the present invention increases the duration of response to treatment, the time to disease progression, PFS, and / or OS.

[0035] Typically, the methods of the present invention include co-administering PSMA-targeted T cell engaging molecules and anti-androgen compounds to patients in one or more treatment cycles. "Treatment cycle" or "cycle" refers to the period of time during which T cell engaging molecules and anti-androgen compounds are administered at a specific dose and dosing interval. According to the methods of the present invention, patients can receive multiple treatment cycles (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more cycles). Treatment cycles can be continuously administered to patients without interruptions or periods during which T cell engaging molecules and anti-androgen compounds are not administered between cycles. Alternatively, a period (e.g., "no treatment period" or "interruption") during which either or both of the T cell engaging molecules and anti-androgen compounds are not administered can be used between treatment cycles. The length of the no treatment period can be adjusted based on the characteristics of the patient and / or the response to treatment.

[0036] Each of these treatment cycles requires the co-administration of the PSMA-targeted T cell engaging molecule with the anti-androgen compound. As used herein, the term "combination" or "combination therapy" refers to the administration of two compounds so that the therapeutic effect of the PSMA-targeted T cell engaging molecule is consistent with the therapeutic effect of the anti-androgen compound in one or more time periods. In addition to the first dose of the anti-androgen compound and the first therapeutic dose of the PSMA-targeted T cell engaging molecule in the first treatment cycle as described in more detail herein, the administration of the PSMA-targeted T cell engaging molecule and the administration of the anti-androgen compound can occur in a substantially simultaneous manner or in a sequential manner (i.e., each compound is administered on a different day in any order). Substantially simultaneous administration includes simultaneous administration, and can be accomplished by administering a single formulation containing two compounds (e.g., a single IV bag containing two compounds) or a separate formulation containing each compound simultaneously (e.g., on the same day). The anti-androgen compound does not need to be administered with the same dosing frequency or dosing interval as the PSMA-targeted T cell engaging molecule. Typically, the anti-androgen compound will be administered at a dose and / or schedule determined for the compound. The anti-androgen compound can be administered on the same day or on a different day of the treatment cycle as the PSMA-targeted T cell engaging molecule. Provided herein are exemplary dosages and dosing schedules for the PSMA-targeted T cell engaging molecules and anti-androgen compounds for administration according to the methods of the invention.

[0037] In certain embodiments, the efficacy of the combination therapy as assessed by any of the above methods is greater than the efficacy of the PSMA-targeted T cell engagement molecule monotherapy and the efficacy of the anti-androgen compound monotherapy. For example, in some embodiments, compared with the PSA50 response produced by the monotherapy of any one compound alone, the PSMA-targeted T cell engagement molecule is administered in combination with an anti-androgen compound to produce a PSA50 response in a greater proportion of prostate cancer patients. In other embodiments, compared with the number of CRs, PRs and / or SDs produced by the monotherapy of any one compound alone, the PSMA-targeted T cell engagement molecule is administered in combination with an anti-androgen compound to produce a greater number of such responses in prostate cancer patients with measurable tumors or lesions, as determined by the RECIST 1.1 standard optionally with PCWG3 modifications. In other embodiments, compared with the duration of response to treatment observed in the monotherapy regimen of any single compound, the time to disease progression, PFS and / or OS, the PSMA-targeted T cell engagement molecule is administered in combination with an anti-androgen compound to increase the duration of response to treatment, the time to disease progression, PFS and / or OS. In some embodiments, co-administration of a PSMA-targeted T cell engaging molecule and an anti-androgen compound results in a synergistic increase in anti-tumor efficacy as assessed by any of the above methods (e.g., PSA response, RECIST 1.1 response, PSMA tumor burden by PET / CT, CTC response, etc.).

[0038] In a preferred embodiment of the method of the present invention, the first treatment cycle (also referred to as the starting cycle) includes administering a first therapeutic dose of PSMA-targeted T cell engagement molecules, followed by a prescribed delay period, and then administering a first dose of an anti-androgen compound. As described in the examples herein, when the start time of treatment of the anti-androgen compound is delayed to about 7 days after the administration of the first therapeutic dose of PSMA-targeted T cell engagement molecules, the number and severity of adverse events are significantly reduced compared to when anti-androgen therapy and the administration of the first dose of PSMA-targeted T cell engagement molecules are started simultaneously. It is not desirable to be bound by theory, because CRS events are most serious and most frequently occur when a therapeutic dose of PSMA-targeted T cell engagement molecules is first administered, it is believed that the start time of treatment of the anti-androgen compound is delayed to when CRS symptoms subside or improve after the administration of the therapeutic dose (e.g., at least 3 days) The safety and tolerability characteristics of the combination therapy can be improved. Therefore, in certain embodiments of the method of the present invention, the first treatment cycle includes administering a first dose of an anti-androgen compound at least 3 days after the administration of the first therapeutic dose of PSMA-targeted T cell engagement molecules. In some embodiments, the first treatment cycle includes administering a first dose of an anti-androgen compound about 3 days to about 14 days, about 4 days to about 10 days, or about 5 days to about 9 days after administering the first therapeutic dose of the PSMA-targeted T cell engaging molecule. The delay period between administering the first therapeutic dose of the PSMA-targeted T cell engaging molecule and administering the first dose of the anti-androgen compound in the first cycle can be about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days. In one embodiment, the first cycle includes administering a first dose of an anti-androgen compound about 5 days after administering the first therapeutic dose of the PSMA-targeted T cell engaging molecule. In another embodiment, the first cycle includes administering a first dose of an anti-androgen compound about 7 days after administering the first therapeutic dose of the PSMA-targeted T cell engaging molecule.

[0039] When a patient begins a course of treatment with a PSMA-targeted T cell engaging molecule, a first cycle or starting cycle is typically administered to the patient. When a patient restarts a course of treatment with a PSMA-targeted T cell engaging molecule, for example, after a non-treatment period, an interruption in dosing (e.g., when the patient has not completed a previous treatment cycle), or after a patient's cancer relapses or progresses, the first cycle regimen described herein may also be administered to the patient. If the patient switches to a course of treatment with a different PSMA-targeted T cell engaging molecule or a different anti-androgen compound, the first cycle regimen may also be administered to the patient. In some embodiments of the methods of the present invention, the duration of the first cycle or starting cycle is about 14 days to about 56 days, such as about 14 days to about 28 days, about 21 days to about 42 days, about 28 days to about 49 days, or about 21 days to about 28 days. In certain embodiments, the duration of the first cycle or starting cycle is about 28 days.

[0040] In one aspect, the method of the present invention comprises administering to a patient a therapeutically effective dose of a PSMA-targeted T cell engagement molecule and a therapeutically effective dose of an anti-androgen compound. "Therapeutically effective dose" or "therapeutic dose" refers to an amount of a compound sufficient to treat or improve prostate cancer or one or more of its symptoms, particularly a state or symptom associated with prostate cancer, or otherwise prevent, hinder, delay or reverse the progression of prostate cancer or any other adverse symptoms associated with prostate cancer. The amount of the therapeutic dose may vary depending on: the characteristics of the patient to be treated; the route of administration; the type, grade or stage of the patient's diagnosed cancer; and the specific PSMA-targeted T cell engagement molecule and anti-androgen compound administered to the patient. The therapeutic dose of the PSMA-targeted T cell engagement molecule and / or anti-androgen compound administered to the patient in the combined treatment method of the present invention may be different from the therapeutic dose of the same compound employed in a monotherapy method. For example, due to, for example, a synergistic anti-tumor effect, the therapeutic dose of one or both compounds may be less than the therapeutic dose of the compound administered as part of a monotherapy. Specific therapeutic doses of PSMA-targeted T cell engaging molecules and anti-androgen compounds can be determined from dose-finding human clinical trials (such as those described in the Examples), or in some cases can be estimated from relevant animal models of the specific cancer to be treated. Suitable doses of specific PSMA-targeted T cell engaging molecules and anti-androgen compounds are described in more detail herein.

[0041] In some embodiments of the methods of the present invention, for example, the first dose of the PSMA-targeted T cell engaging molecule and / or the anti-androgen compound administered to the patient in the first cycle is a therapeutic dose. In other embodiments, for example, the first dose of the PSMA-targeted T cell engaging molecule and / or the anti-androgen compound administered to the patient in the first cycle is not a therapeutic dose. For example, the first dose of the PSMA-targeted T cell engaging molecule and / or the anti-androgen compound administered to the patient may be a dose (e.g., a titration dose or a pre-excitation dose) lower than the therapeutic dose. When the patient is first exposed to the PSMA-targeted T cell engaging molecule, such a pre-excitation dose, in particular the pre-excitation dose of the PSMA-targeted T cell engaging molecule, may be used to reduce the number or severity of adverse events (such as CRS events). As used herein, the term "pre-excitation dose" refers to such a dose or amount of a PSMA-targeted T cell engaging molecule that induces the patient to subsequently administer a therapeutic dose of a PSMA-targeted T cell engaging molecule, so that the administration of the therapeutic dose produces fewer or less severe adverse events (e.g., fewer or less severe CRS events) in the patient. In some embodiments, the priming dose may be lower than the therapeutic dose but is a dose that is sufficient to prime the patient's T cells (e.g., to release cytokines) such that subsequent administration of a larger or therapeutic dose of the T cell engagement molecule produces an attenuated increase in cytokine secretion. In certain embodiments, the priming dose is sufficient to increase the proportion of activated peripheral T cells in the patient (e.g., increase the proportion of CD69+CD8+ peripheral T cells) relative to the proportion of activated T cells in the patient before receiving the dose of the T cell engagement molecule. The priming dose may be a portion of the therapeutic dose, such as about 10% to about 80% of the therapeutic dose, about 20% to about 75% of the therapeutic dose, about 15% to about 50%, about 25% to about 70%, or about 30% to about 60%. In one embodiment, the priming dose of the PSMA-targeted T cell engagement molecule is about 30% of the therapeutic dose. In another embodiment, the priming dose of the PSMA-targeted T cell engagement molecule is about 60% of the therapeutic dose. One or more priming doses of the PSMA-targeted T cell engagement molecule may be administered to the patient prior to administering the therapeutic dose. In certain embodiments of the methods of the invention, the first dose of the anti-androgen compound administered to the patient in the first cycle is a therapeutic dose, and the first dose of the PSMA-targeted T cell engaging molecule administered to the patient in the first cycle is a priming dose. In certain other embodiments of the methods of the invention, the first dose of the anti-androgen compound administered to the patient in the first cycle is a therapeutic dose, and the first dose of the PSMA-targeted T cell engaging molecule administered to the patient in the first cycle is a therapeutic dose.

[0042] In certain embodiments of the methods of the present invention, the first cycle further comprises administering one or more priming doses of PSMA-targeted T cell engaging molecules to the patient prior to administering the first therapeutic dose of the T cell engaging molecule. In such embodiments, the first therapeutic dose of the T cell engaging molecule may be administered from about 1 day to about 21 days, from about 1 day to about 14 days, or from about 1 day to about 7 days after the first priming dose of the PSMA-targeted T cell engaging molecule is administered to the patient. In certain embodiments, the first therapeutic dose of the PSMA-targeted T cell engaging molecule is administered to the patient about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days after the first priming dose of the PSMA-targeted T cell engaging molecule is administered. In embodiments where two or more priming doses of the PSMA-targeted T cell engaging molecule are administered to the patient, the priming doses may be the same or they may be different. For example, in some such embodiments, the priming dose of the PSMA-targeted T cell engaging molecule may be increased in a series of increasing dose steps at one or more subsequent dosing intervals. Such a stepwise dosing regimen may be used in embodiments where two or more priming doses are administered prior to administering a therapeutic dose during a first cycle, and may include one or more dose steps (eg, one or more dose increases).

[0043] The anti-androgen compound used according to the method of the present invention refers to a compound that inhibits or blocks the biological activity of androgens in one or more cells or tissues of the body. In some embodiments, the anti-androgen compound inhibits or blocks the synthesis of androgens, for example, by inhibiting the function of the CYP17A1 enzyme. Exemplary androgen biosynthesis inhibitors include abiraterone and ketoconazole. In other embodiments, the anti-androgen compound is an androgen receptor antagonist, such as flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide or darolutamide. In certain embodiments, the anti-androgen compound used in the method of the present invention is abiraterone, abiraterone acetate, ketoconazole, flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide or darolutamide. In other embodiments, the anti-androgen compound is enzalutamide, abiraterone, abiraterone acetate, apalutamide or darolutamide. In a specific embodiment, the anti-androgen compound used in the method of the present invention is enzalutamide. In another specific embodiment, the antiandrogen compound used in the methods of the present invention is abiraterone or abiraterone acetate.

[0044] In certain embodiments of the methods of the present invention, the anti-androgen compound is administered orally. Suitable therapeutic oral doses of anti-androgen compounds can be about 50 mg to about 1,000, about 150 mg to about 800 mg, or about 200 mg to about 600 mg, depending on the specific anti-androgen compound used. Such doses can be administered once a day, twice a day, or three times a day over the duration of the treatment cycle. In certain embodiments, the anti-androgen compound is orally administered to the patient once a day (QD). In some embodiments, the oral dose is in the form of a tablet or capsule. In some such embodiments, each tablet or capsule may contain a unit dose less than the total therapeutic dose to be administered, so that more than one tablet or capsule is administered to the patient at each prescribed dosing interval.

[0045] In some embodiments, the anti-androgen compound is enzalutamide, and the therapeutic oral dose is about 40 mg to about 160 mg once a day (QD). In a specific embodiment of the method of the present invention, enzalutamide is orally administered to the patient once a day at a dose of 160 mg (e.g., four 40 mg tablets or capsules or two 80 mg tablets). In other embodiments, the anti-androgen compound is abiraterone or abiraterone acetate, and the therapeutic oral dose is about 250 mg to about 1,000 mg or about 500 mg to about 1,000 mg once a day. In one such embodiment, abiraterone or abiraterone acetate is orally administered to the patient once a day at a dose of 1,000 mg (e.g., four 250 mg tablets or two 500 mg tablets). In embodiments where abiraterone or abiraterone acetate is administered to a patient, a 5 mg dose of prednisone may be orally administered twice a day (BID). In other embodiments where abiraterone or abiraterone acetate is administered to a patient, a 10 mg dose of prednisolone may be orally administered once a day. In certain other embodiments of the methods of the present invention, the anti-androgen compound is darolutamide, and the therapeutic oral dose is about 300 mg to about 600 mg twice a day (BID). In one such embodiment, darolutamide is orally administered to the patient twice a day at a dose of 600 mg (e.g., two 300 mg tablets). In other embodiments, the anti-androgen compound is apalutamide, and the therapeutic oral dose is about 120 mg to about 240 mg once a day (QD). In one such embodiment, apalutamide is orally administered to the patient once a day at a dose of 240 mg (e.g., four 60 mg tablets).

[0046] The methods described herein include administering to a patient a PSMA-targeted T cell engaging molecule, which refers to a T cell engaging molecule that specifically binds to PSMA and CD3. The term "T cell engaging molecule" refers to a molecule comprising at least one domain in which the structure is derived from or comprises the minimum structural features of an antibody (e.g., a full-length immunoglobulin molecule) that allows specific binding to an antigen on the surface of a T cell (such as CD3). Therefore, the T cell engaging molecule according to the present invention generally comprises one or more binding domains, each of which will typically comprise the minimum structural requirements of an antibody that allows specific target binding. For example, this minimum requirement can be defined by the presence of at least three light chain "complementarity determining regions" or CDRs (i.e., CDRL1, CDRL2, and CDRL3 in the VL region) and / or three heavy chain CDRs (i.e., CDRH1, CDRH2, and CDRH3 in the VH region), preferably all six CDRs from both the light chain and heavy chain variable regions. The T cell engaging molecule according to the present invention may comprise domains or regions (e.g., CDRs or variable regions) from monoclonal antibodies, chimeric antibodies, humanized antibodies, and human antibodies.

[0047] Preferably, the T cell engaging molecules used in the methods of the present invention are proteins and comprise one or more polypeptide chains. As used herein, a polypeptide refers to an amino acid polymer comprising at least 50 amino acids, preferably at least 100 amino acids. In some embodiments, the T cell engaging molecules administered according to the methods of the present invention are single-chain polypeptides. In other embodiments, the T cell engaging molecules administered according to the methods of the present invention comprise two or more polypeptide chains—for example, polypeptide dimers or multimers. In certain embodiments, the T cell engaging molecules administered according to the methods of the present invention comprise four polypeptide chains and may, for example, have the form of an antibody or immunoglobulin. In certain other embodiments, the T cell engaging molecules administered according to the methods of the present invention comprise three polypeptide chains.

[0048] As used herein, the term "antibody" generally refers to a tetrameric immunoglobulin comprising two light chain polypeptides (each about 25 kDa) and two heavy chain polypeptides (each about 50-70 kDa). The term "light chain" or "immunoglobulin light chain" refers to a polypeptide comprising a single immunoglobulin light chain variable region (VL) and a single immunoglobulin light chain constant domain (CL) from the amino terminus to the carboxyl terminus. The immunoglobulin light chain constant domain (CL) can be a human kappa (κ) or human lambda (λ) constant domain. The term "heavy chain" or "immunoglobulin heavy chain" refers to a polypeptide comprising a single immunoglobulin heavy chain variable region (VH), an immunoglobulin heavy chain constant domain 1 (CH1), an immunoglobulin hinge region, an immunoglobulin heavy chain constant domain 2 (CH2), an immunoglobulin heavy chain constant domain 3 (CH3) and optionally an immunoglobulin heavy chain constant domain 4 (CH4) from the amino terminus to the carboxyl terminus. Heavy chains are classified into mu (μ), delta (Δ), gamma (γ), alpha (α), and epsilon (ε) chains, and they define the antibody isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Antibodies of the IgG and IgA categories are further subdivided into several subclasses, namely IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2, respectively. The heavy chains in IgG, IgA, and IgD antibodies have three constant domains (CH1, CH2, and CH3), while the heavy chains in IgM and IgE antibodies have four constant domains (CH1, CH2, CH3, and CH4). The immunoglobulin heavy chain constant domains can be from any immunoglobulin isotype, including subtypes. The antibody chains are linked together via inter-polypeptide disulfide bonds between the CL domain and the CH1 domain (i.e., between the light chain and the heavy chain) and between the hinge regions of the two antibody heavy chains.

[0049] The variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FRs) connected by three hypervariable regions (more commonly referred to as "complementarity determining regions" or CDRs). The CDRs from the two chains of each heavy and light chain pair are typically aligned by the framework regions to form a structure that specifically binds to a specific epitope on a target protein (e.g., PSMA or CD3). From N-terminus to C-terminus, both naturally occurring light and heavy chain variable regions typically follow the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. A numbering system has been designed to assign numbers to the amino acids that occupy positions in each of these domains. This numbering system is defined in the following literature: Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, National Institutes of Health (NIH), Bethesda, Maryland); or Chothia and Lesk, 1987, J. Mol. Biol. [Journal of Molecular Biology] 196:901-917; Chothia et al., 1989, Nature [Nature] 342:878-883. The CDRs and FRs of a given antibody can be identified using this system. Other numbering systems for amino acids in immunoglobulin chains include (International ImMunoGeneTics Information System; Lefranc et al., Dev. Comp. Immunol. 29: 185-203; 2005) and AHo (Honegger and Pluckthun, J. Mol. Biol. 309(3): 657-670; 2001).

[0050] The T cell engaging molecule used in the method of the present invention is preferably at least a bispecific T cell engaging molecule. The term "bispecific T cell engaging molecule" refers to a molecule that is capable of specifically binding to two different antigens. In the context of the present invention, such bispecific T cell engaging molecules specifically bind to PSMA (e.g., human PSMA) on the cell surface of target cells and CD3 (e.g., human CD3) on the cell surface of T cells. The term "PSMA-targeted T cell engaging molecule" is used herein to refer to a T cell engaging molecule that specifically binds to PSMA and CD3. When the binding affinity of a T cell engaging molecule to a target antigen under similar binding assay conditions is significantly higher than its affinity to other unrelated proteins and can therefore be distinguished, the T cell engaging molecule or its binding domain "specifically binds" to the antigen. A T cell engaging molecule or its binding domain that specifically binds to an antigen can be expressed as ≤1×10 -6 The equilibrium dissociation constant (KD ) binds to the antigen. D ≤1×10 -8 M, the T cell engagement molecule or its binding domain specifically binds to the antigen with "high affinity". In one embodiment, the T cell engagement molecule or its binding domain used in the method of the present invention has a specific affinity of ≤5×10 -7 M of K D Binds to human PSMA and / or human CD3. In another embodiment, the T cell engaging molecule or its binding domain used in the method of the present invention is ≤1×10 -7 M of K D Binds to human PSMA and / or human CD3. In another embodiment, the T cell engaging molecule or its binding domain used in the method of the present invention is ≤5×10 -8 M of K D Binds to human PSMA and / or human CD3. In another embodiment, the T cell engaging molecule or its binding domain used in the method of the present invention is ≤2×10 -8 M of K D Binds to human PSMA and / or human CD3. In certain embodiments, the T cell engaging molecule or its binding domain used in the method of the present invention is ≤1×10 -8 M of K D Binds to human PSMA and / or human CD3. In other embodiments, the T cell engaging molecule or its binding domain used in the method of the present invention is ≤1×10 -9 M of K D Binds to human PSMA and / or human CD3.

[0051] Affinity is determined using a variety of techniques, one example of which is an affinity ELISA assay. In various embodiments, affinity is determined by surface plasmon resonance (e.g., based on Using this method, the association rate constant (k a , with M -1 s -1 ) and the dissociation rate constant (k d , with s -1 Equilibrium dissociation constant (K D , represented by M) can then be calculated from the ratio of the kinetic rate constants (k d / k a) calculation. In some embodiments, affinity is determined by a kinetic method, such as the kinetic exclusion assay (KinExA) described in Rathanaswami et al., Analytical Biochemistry, Vol. 373: 52-60, 2008. Using the KinExA assay, the equilibrium dissociation constant (K expressed in M) can be measured. D ) and the association rate constant (in M -1 s -1 k a ). Dissociation rate constant (in s -1 k d ) can be calculated from these values ​​(K D ×k a In other embodiments, the biofilm interferometry method is used, such as described in Kumaraswamy et al., Methods Mol. Biol., Vol. 1278: 165-82, 2015 and used for The affinity was determined by the method in the ELISA system (Pall ForteBio). The kinetic constant (k a and k d ) and affinity constant (K D ) can be calculated in real time using biofilm interferometry. In some embodiments, the T cell engaging molecules or their binding domains described herein exhibit desired properties, such as by K d (dissociation rate constant) measured about 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 s -1 or lower binding affinity to human PSMA and / or human CD3 (lower values ​​indicate higher binding affinity), and / or by K D (equilibrium dissociation constant) measured about 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 M or lower binding affinity to human PSMA and / or human CD3 (lower values ​​indicate higher binding affinity).

[0052] In some embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention can be antibodies and have the general structure of a full-length immunoglobulin. For example, a PSMA-targeted T cell engaging molecule can comprise two full-length antibody heavy chains and two full-length antibody light chains. In specific embodiments, the T cell engaging molecule is a heterodimeric antibody (interchangeably used herein with "heteroimmunoglobulin" or "heteroIg"), which refers to an antibody comprising two different light chains and two different heavy chains. For example, in some embodiments, the heterodimeric antibody comprises a light chain and a heavy chain from an anti-PSMA antibody and a light chain and a heavy chain from an anti-CD3 antibody.

[0053] The PSMA-targeted T cell engaging molecules used in the methods of the present invention may also comprise fragments of full-length antibodies, such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab') 2 or "rIgG" (a "half antibody" consisting of a heavy chain and a light chain). The PSMA-targeted T cell engaging molecules according to the present invention may also comprise modified fragments of antibodies. Examples of such modified fragments are, but are not limited to, single-chain variable fragments (scFv), di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, single-chain Fab (scFab), Fab 2 Fab 3 , diabodies, single-chain diabodies, tandem diabodies (Tandab), tandem di-scFv, tandem tri-scFv, "minibodies" (which are exemplified by the following structure: (VH-VL-CH3) 2 、(scFv-CH3) 2 , ((scFv) 2 -CH3+CH3)、((scFv) 2 -CH3) or (scFv-CH3-scFv) 2 ), multimeric antibodies such as triabodies or tetrabodies, and single domain antibodies (such as nanobodies or single variable domain antibodies comprising only one variable region, which domain may be VHH, VH or VL, which specifically binds to an antigen or target independently of other variable regions or domains). In some embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention comprise a binding domain derived from a single variable domain antibody comprising only a heavy chain variable region. In some such embodiments, the binding domain comprising a heavy chain variable region may be fused to one or more constant regions from an immunoglobulin heavy chain, such as a CH2, CH3 or Fc domain.

[0054] In certain embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention are multivalent. The valence of a T cell engaging molecule indicates the number of individual antigen binding domains within the T cell engaging molecule. For example, in the context of the present invention, the terms "monovalent," "bivalent," and "tetravalent" with respect to T cell engaging molecules refer to T cell engaging molecules having one, two, and four antigen binding domains, respectively. Thus, multivalent T cell engaging molecules comprise two or more antigen binding domains. T cell engaging molecules may have more antigen binding domains than specificity (e.g., a higher valence). For example, a T cell engaging molecule having two antigen binding domains for a first target (e.g., PSMA) and one antigen binding domain for a second target (CD3) - or vice versa - is considered to be trivalent (three antigen binding domains) and bispecific (binding to two antigens). In certain embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention are bivalent. Thus, such bispecific, bivalent T cell engager molecules contain two antigen binding domains: one antigen binding domain to PSMA (eg, human PSMA) and one antigen binding domain to CD3 (eg, human CD3).

[0055] Exemplary PSMA-targeted T cell engaging molecules used in the methods of the invention are described in more detail herein. Other suitable PSMA-targeted T cell engaging molecules that can be administered in the combined treatment methods of the invention are known in the art, such as those described in WO 2010 / 037836, WO 2011 / 121110, WO 2012 / 145714, WO 2017 / 023761, WO 2017 / 121905, WO 2017 / 134158, WO 2018 / 098356, WO 2019 / 224718, WO 2020 / 206330, and WO 2021 / 231976, all of which are hereby incorporated by reference in their entirety. An exemplary range of therapeutic doses of PSMA-targeted T cell engaging molecules that can be administered according to the methods of the present invention may include, but are not limited to, doses of about 50 μg to about 200 mg, about 200 μg to about 80 mg, about 90 μg to about 30 mg, about 300 μg to about 15 mg, about 150 μg to about 2 mg, about 6 mg to about 25 mg, about 1 mg to about 20 mg, about 10 mg to about 100 mg, or about 50 mg to about 150 mg. Depending on the specific PSMA-targeted T cell engaging molecule used and its half-life, a therapeutic dose of PSMA-targeted T cell engaging molecules can be administered at a dosing interval of once a week (QW), once every two weeks (Q2W), once every three weeks (Q3W), or once a month (QM). In certain embodiments, a therapeutic dose of PSMA-targeted T cell engaging molecules is administered once every 7 days or once a week. In certain other embodiments, a therapeutic dose of PSMA-targeted T cell engaging molecules is administered once every 14 days or once every two weeks.

[0056] In some embodiments of the methods described herein, the PSMA-targeted T cell engaging molecules are administered to the patient parenterally. Parenteral administration refers to administration of the molecule by a route other than the gastrointestinal tract and can include intraperitoneal, intramuscular, intravenous, intraarterial, intradermal, subcutaneous, intracerebral, intracerebroventricular, and intrathecal administration. In certain embodiments of the methods of the invention, the PSMA-targeted T cell engaging molecules are administered to the patient intravenously. In other embodiments of the methods of the invention, the PSMA-targeted T cell engaging molecules are administered to the patient subcutaneously.

[0057] Parenteral administration or intravenous administration can be by injection (e.g., using a needle and syringe) or by infusion (e.g., via a catheter and pump system). It is envisioned that the administration of the PSMA-targeted T cell engaging molecules according to some embodiments of the methods of the present invention is performed via intravenous injection or via intravenous infusion. Typically, intravenous (IV) infusions are administered via lines, ports, or catheters (small flexible tubes) (such as central venous access or central venous catheters (CVCs), which are catheters placed in large veins; or peripheral venous catheters (PVCs), which are catheters placed in peripheral veins). Typically, the catheter or line can be placed in the neck (in the internal jugular vein), the chest (in the subclavian vein or axillary vein), the groin (in the femoral vein), or through a vein in the arm (also known as a PICC line, or a peripherally inserted central catheter). The central IV line has a catheter that advances through a vein and flows into a large central vein (usually the superior vena cava, the inferior vena cava, or even the right atrium of the heart). Peripheral intravenous (PIV) lines are used for peripheral intravenous (intravenous in arms, hands, legs, and feet). A port is a central venous line with no external connector; instead, it has a small reservoir covered with silicone rubber and implanted under the skin. Medication is administered intermittently by placing a small needle through the skin, piercing the silicone, and into the reservoir. When the needle is withdrawn, the reservoir cap reseals itself. The cap can accept hundreds of needles during its life.

[0058] In certain embodiments of the methods of the present invention, one or more doses of PSMA-targeted T cell engaging molecules are administered to a patient by continuous intravenous infusion over an extended period of time. As used herein, continuous intravenous infusion refers to a controlled method of intravenous administration of PSMA-targeted T cell engaging molecules that is administered uninterruptedly or substantially uninterruptedly over a period of time exceeding about 3 hours, more typically exceeding about 6 hours. Continuous intravenous infusion can be administered by a fluid delivery device or a small pump system, which includes a fluid drive mechanism for driving the fluid out of the reservoir and an actuating mechanism for actuating the drive mechanism. The pump system for such administration may include a needle or cannula for penetrating the patient's skin and delivering the infusion solution into the patient's body. The pump system can be connected to the patient for 24 hours up to several days. Pump systems for delivering intravenous infusions are known in the art. Depending on the duration of the continuous infusion, it may be necessary to replace or replace the bag or reservoir containing the infusion solution in the pump system. During the replacement of the bag or reservoir in the pump system, a temporary interruption of the infusion flow that would not otherwise be interrupted may occur. Such temporary interruptions due to replacement of the bag or reservoir do not constitute a break or substantial break in intravenous administration, and the period of time during which the bag or reservoir is replaced will still be considered to be within the continuous intravenous infusion period as that term is used herein.

[0059] In other embodiments of the methods of the present invention, one or more doses of the PSMA-targeted T cell engaging molecule are administered by intravenous push. As used herein, an intravenous push (interchangeably used herein with a short intravenous infusion) refers to an intravenous infusion of a small volume (e.g., 20 mL to 100 mL) administered over a period of up to three hours, more typically over a period of about 30 min to about 90 min. In some embodiments of the methods of the present invention, the intravenous push is an intravenous infusion administered over about 30 min to about 60 min. In certain embodiments of the methods of the present invention, the intravenous push is an intravenous infusion administered over about 60 min (e.g., 55 min to 65 min).

[0060] Combinations of administration routes can be used to administer PSMA-targeted T cell engaging molecules according to the methods of the present invention. For example, in some embodiments, particularly in the first cycle, a first dose (e.g., a priming dose) of a PSMA-targeted T cell engaging molecule can be administered by continuous intravenous infusion over an extended period of time (e.g., over 1 to 7 days), followed by subsequent doses (e.g., therapeutic doses) by intravenous push or subcutaneous injection. Thus, in some embodiments of the methods of the present invention, in the first cycle, a first dose (e.g., a first priming dose) of a PSMA-targeted T cell engaging molecule is administered by continuous intravenous infusion over a period of at least 24 hours (e.g., over a period of 1 to 14 days, 1 to 7 days, or 1 to 5 days). In a specific embodiment, in the first cycle, a first dose (e.g., a first priming dose) of a PSMA-targeted T cell engaging molecule is administered by continuous intravenous infusion over a period of about 3 days (i.e., a 72-hour infusion). In these and other embodiments, the continuous intravenous infusion is administered at a constant flow rate—that is, the continuous intravenous infusion delivers a dose of the PSMA-targeted T cell engaging molecule at a constant rate during the infusion period. For example, for a dose of 3 mg, a continuous intravenous infusion given at a constant flow rate over 3 days will deliver the dose at a rate of 1 mg / day, such that a total dose of 3 mg will be delivered at the completion of the 3-day infusion period. Alternatively, in some embodiments, a continuous intravenous infusion can be given at a variable flow rate, such that the dose is delivered at a different dose each day during the infusion period. For example, in one such embodiment, the flow rate of the continuous infusion can be adjusted such that an increasing dose is given each day during the infusion period to deliver a total dose at the completion of the infusion period.

[0061] In some embodiments of the methods of the present invention, the first cycle includes administering a dose of a PSMA-targeted T cell engagement molecule at a dosing interval of once every 7 days (or once a week), and administering a dose of an anti-androgen compound at a dosing interval of once a day, wherein the first dose of the anti-androgen compound is administered at least 3 days after the first therapeutic dose of the PSMA-targeted T cell engagement molecule is administered. An exemplary dosing schedule according to such embodiments (wherein the duration of the first cycle is 28 days) includes administering a dose of a PSMA-targeted T cell engagement molecule (e.g., by intravenous push) on each of days 1, 8, 15, and 22 of the first cycle, and administering a dose of an anti-androgen compound (e.g., by oral administration) once a day on each of days 15 to 28 of the first cycle. In other embodiments of the methods of the present invention, the first cycle includes administering a dose of a PSMA-targeted T cell engagement molecule at a dosing interval of once every 14 days (or once every two weeks), and administering a dose of an anti-androgen compound at a dosing interval of once a day, wherein the first dose of the anti-androgen compound is administered at least 3 days after the first therapeutic dose of the PSMA-targeted T cell engagement molecule is administered. An exemplary dosing schedule according to these embodiments (wherein the duration of the first cycle is 28 days) includes administering a dose of a PSMA-targeted T cell engaging molecule (e.g., by intravenous bolus) on each of days 1 and 15 of the first cycle, and administering a dose of an anti-androgen compound once a day on each of days 15 to 28 of the first cycle (e.g., by oral administration). In any of the foregoing embodiments, all doses of the PSMA-targeted T cell engaging molecule administered during the first cycle may be the same and be therapeutic doses. In alternative embodiments, the first dose of the PSMA-targeted T cell engaging molecule (e.g., a dose administered on day 1 of the cycle) may be different from all subsequent doses of the T cell engaging molecule administered during the first cycle. For example, the first dose of the PSMA-targeted T cell engaging molecule may be a priming dose as described herein, and all subsequent doses of the PSMA-targeted T cell engaging molecule may be therapeutic doses.

[0062] In certain embodiments of the methods of the invention, the first cycle comprises administering a priming dose of a PSMA-targeted T cell engaging molecule by continuous intravenous infusion over about 3 days, followed by administering a therapeutic dose of a PSMA-targeted T cell engaging molecule by intravenous push at a dosing interval of 7 or 14 days, and administering a dose of an anti-androgen compound at a dosing interval once a day, wherein the first dose of the anti-androgen compound is administered at least 3 days after the first therapeutic dose of the PSMA-targeted T cell engaging molecule is administered. In embodiments where the first cycle has a duration of 28 days, an exemplary dosing schedule may include administering a priming dose (which may be any priming dose described herein) of a PSMA-targeted T cell engaging molecule by continuous intravenous infusion over days 1 to 3 of the first cycle, administering a therapeutic dose of a PSMA-targeted T cell engaging molecule by intravenous push on days 8 and 22 of the first cycle, and administering a dose of an anti-androgen compound orally once a day on each of days 15 to 28 of the first cycle.

[0063] In some embodiments, the method of the present invention further includes administering to the patient at least one maintenance cycle of anti-androgen compounds and PSMA-targeted T cell engagement molecules after the first cycle or the start cycle. As used herein, a "maintenance cycle" is such a treatment cycle in which the two compounds are administered at a dose and dosing frequency designed to maintain the exposure threshold level of the PSMA-targeted T cell engagement molecule and the anti-androgen compound at the patient's therapeutic level. In certain embodiments, the dosing frequency used in the maintenance cycle of the PSMA-targeted T cell engagement molecule, the anti-androgen compound, or the two compounds is lower than the dosing frequency used in the first cycle (i.e., the dosing interval in the maintenance cycle is longer than the dosing interval in the first cycle). In some embodiments, the maintenance cycle is administered immediately after the first cycle is completed. Therefore, in such embodiments, there is no treatment period or interruption between the end of the first cycle or the start cycle and the beginning of the maintenance cycle. In one such embodiment, the maintenance cycle is administered the next day after the first cycle or the start cycle is completed. In other embodiments, there is a treatment period or interruption between the completion of the first cycle or the start cycle and the administration of the maintenance cycle. Preferably, the treatment-free period between the first or starting cycle and the maintenance cycle is no longer than the dosing interval of the PSMA-targeted T cell engaging molecule used in the maintenance cycle. In one embodiment, the maintenance cycle is administered about 7 days after the completion of the first or starting cycle. In another embodiment, the maintenance cycle is administered about 14 days after the completion of the first or starting cycle.

[0064] Depending on the duration of treatment required for the patient, multiple maintenance cycles (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles) may be administered to the patient. For example, the patient may receive a maintenance cycle of a PSMA-targeted T cell engaging molecule in combination with an anti-androgen compound until the patient reaches a desired response level, such as a complete response or a partial response. In some embodiments, two or more maintenance cycles are administered to the patient. In other embodiments, four or more maintenance cycles are administered to the patient. In yet other embodiments, six to twelve maintenance cycles are administered to the patient. In certain embodiments, the maintenance cycles are administered continuously, with no treatment-free periods between maintenance cycles. If treatment interruption is required, the duration of the treatment-free period should ideally be no greater than twice the dosing interval of the PSMA-targeted T cell engaging molecule used in the maintenance cycle. For example, if the dosing interval of the PSMA-targeted T cell engaging molecule used in the maintenance cycle is once every 14 days (e.g., once every two weeks), the treatment-free period between maintenance cycles will preferably be about 28 days or less.

[0065] In certain embodiments of the methods of the present invention, the maintenance cycle includes administering a therapeutic dose of a PSMA-targeted T cell engagement molecule (such as any therapeutic dose described herein) at a dosing interval of at least 7 days, and orally administering an anti-androgen compound once a day on each day of the cycle. For example, in some embodiments of the methods of the present invention, the maintenance cycle includes administering a therapeutic dose of a PSMA-targeted T cell engagement molecule once every 7 days (e.g., once a week, QW dosing) by intravenous bolus or subcutaneous injection, and orally administering an anti-androgen compound once a day on each day of the cycle. In other embodiments of the methods of the present invention, the maintenance cycle includes administering a therapeutic dose of a PSMA-targeted T cell engagement molecule once every 14 days (e.g., once every two weeks, Q2W dosing) by intravenous bolus or subcutaneous injection, and orally administering an anti-androgen compound once a day on each day of the cycle. In other embodiments, a therapeutic dose of a PSMA-targeted T cell engagement molecule may be administered by intravenous bolus or subcutaneous injection at a longer dosing interval (such as once every three weeks or once every four weeks) during the maintenance cycle. In such embodiments, the anti-androgen compound may continue to be administered orally once a day on each day of the cycle. Preferably, the therapeutic dose of the PSMA-targeted T cell engaging molecule administered during the maintenance period is the same at each dosing interval (e.g., each weekly or biweekly dosing interval) (e.g., a fixed dose for the entire maintenance period). In these and other embodiments, the therapeutic dose and dosing frequency of the PSMA-targeted T cell engaging molecule administered during the maintenance period is the same from one maintenance period to the next.

[0066] According to some embodiments of the methods of the present invention, the duration of the maintenance cycle is from about 14 days to about 60 days, such as from about 14 days to about 28 days, from about 21 days to about 42 days, from about 28 days to about 49 days, from about 28 days to about 56 days, or from about 21 days to about 28 days. In certain embodiments, the duration of the maintenance cycle is about 28 days. In some such embodiments, a therapeutic dose of PSMA-targeted T cell engagement molecule is administered by intravenous push injection on days 1 and 15 of each maintenance cycle, and an anti-androgen compound is administered orally once a day on each day of the maintenance cycle (i.e., each day of days 1 to 28). In other embodiments where the duration of the maintenance cycle is about 28 days, a therapeutic dose of PSMA-targeted T cell engagement molecule is administered by intravenous push injection on days 1, 8, 15, and 22 of each maintenance cycle, and an anti-androgen compound is administered orally once a day on each day of the maintenance cycle (i.e., each day of days 1 to 28).

[0067] In some embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention comprise a first binding domain that specifically binds to PSMA (e.g., human PSMA) and a second binding domain that specifically binds to CD3 (e.g., human CD3). As used herein, the term "antigen binding domain" is used interchangeably with "binding domain" and refers to a region of a T cell engaging molecule that contains amino acid residues that interact with an antigen and impart specificity and affinity to the T cell engaging molecule for the antigen. In certain embodiments, one or more binding domains of a T cell engaging molecule may be derived from an antibody or an antigen binding fragment thereof. For example, the binding domain of a PSMA-targeted T cell engaging molecule used in the methods of the present invention may comprise one or more CDRs from the light chain and heavy chain variable regions of an antibody that specifically binds to human PSMA and / or human CD3. In some embodiments, the anti-PSMA binding domain of the T cell engaging molecule comprises all six CDRs of the heavy chain and light chain variable regions of an anti-PSMA antibody described herein or known in the art, and the anti-CD3 binding domain of the T cell engaging molecule comprises all six CDRs of the heavy chain and light chain variable regions of an anti-CD3 antibody described herein or known in the art. In some embodiments, the binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the present invention (anti-PSMA binding domain, anti-CD3 binding domain, or both) comprises Fab, Fab', F(ab'), 2In one embodiment, both binding domains of the PSMA-targeted T cell engaging molecule are Fab fragments. In another embodiment, one binding domain of the PSMA-targeted T cell engaging molecule is a Fab fragment and the other binding domain is a scFv. In yet another embodiment, both binding domains of the PSMA-targeted T cell engaging molecule are scFv. In yet another embodiment, one binding domain of the PSMA-targeted T cell engaging molecule is a nanobody and the other binding domain is a Fab fragment.

[0068] As used in the context of the present invention, "antigen-binding fragment" is used interchangeably herein with "binding fragment" or "fragment", and is a portion of an antibody that lacks at least some of the amino acids present in a full-length heavy chain and / or light chain, but is still capable of specific binding to an antigen. Antigen-binding fragments include, but are not limited to, single-chain variable fragments (scFv), nanobodies (e.g., VH domains of heavy chain antibodies only (e.g., camelid heavy chain antibodies); VHH fragments, see Cortez-Retamozo et al., Cancer Research, Vol. 64: 2853-57, 2004), Fab fragments, Fab' fragments, F(ab') fragments, 2 In some embodiments, the antigen binding fragment comprises at least one CDR from an antibody bound to an antigen, for example, a heavy chain CDR3 from an antibody bound to an antigen. In other embodiments, the antigen binding fragment comprises all three CDRs from the heavy chain of an antibody bound to an antigen or all three CDRs from the light chain of an antibody bound to an antigen. In other embodiments, the antigen binding fragment comprises all six CDRs (three from the heavy chain and three from the light chain) from an antibody bound to an antigen.

[0069] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment containing all domains except the first domain of the constant region of the immunoglobulin heavy chain. The Fab fragment contains the variable domains from the light chain and the heavy chain, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Thus, a "Fab fragment" consists of one immunoglobulin light chain (the light chain variable region (VL) and constant region (CL)) and the CH1 domain and variable region (VH) of one immunoglobulin heavy chain. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule. A "Fd fragment" contains the VH and CH1 domains from an immunoglobulin heavy chain. The Fd fragment represents the heavy chain component of a Fab fragment.

[0070] An "Fc fragment" or "Fc domain" of an immunoglobulin typically comprises two constant domains, a CH2 domain and a CH3 domain, and optionally a CH4 domain. In certain embodiments, the PSMA-targeted T cell engaging molecule used in the methods of the present invention comprises an Fc domain from an immunoglobulin. The Fc domain can be an Fc domain from an IgG1, IgG2, IgG3, or IgG4 immunoglobulin. In some embodiments, the Fc domain comprises the CH2 and CH3 domains from a human IgG1 or human IgG2 immunoglobulin. The Fc domain can retain effector functions, such as C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody dependent cell-mediated cytotoxicity (ADCC), and phagocytosis. In other embodiments, the Fc domain can be modified to reduce or eliminate effector functions.

[0071] A "Fab' fragment" is a Fab fragment that has one or more cysteine ​​residues from the antibody hinge region at the C-terminus of the CH1 domain.

[0072] “F(ab') 2 The "Fab" fragment is a bivalent fragment comprising two Fab' fragments connected by a disulfide bridge between the heavy chains in the hinge region.

[0073] The "Fv" fragment is the smallest fragment that contains a complete antigen recognition and binding site from an antibody. This fragment consists of a dimer of an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) in tight non-covalent association. It is in this configuration that the three CDRs of each variable region interact to limit the antigen binding site to the surface of the VH-VL dimer. A single light or heavy chain variable region (or half of an Fv fragment containing only three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, although its affinity is lower than that of the entire binding site containing both VH and VL.

[0074] A “single-chain variable fragment” or “scFv fragment” comprises the VH and VL regions of an antibody, wherein these regions are present in a single polypeptide chain, and optionally comprises a peptide linker between the VH and VL regions that enables the Fv to form the desired structure for antigen binding (see, e.g., Bird et al., Science, Vol. 242: 423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. USA, Vol. 85: 5879-5883, 1988).

[0075] "Nano antibodies" are the heavy chain variable regions of heavy chain antibodies. Such variable domains are the smallest fully functional antigen-binding fragments in such heavy chain antibodies, with a molecular weight of only 15 kDa. See Cortez-Retamozo et al., Cancer Research [Cancer Research] 64: 2853-57, 2004. Functional heavy chain antibodies without light chains are naturally present in certain animal species (such as nurse sharks, wobbegong sharks and camelids such as camels, dromedaries, alpacas and llamas). In these animals, the antigen binding site is reduced to a single domain, i.e., the VHH domain. These antibodies only use the heavy chain variable region to form an antigen binding region, i.e., these functional antibodies are only heavy chain homodimers (referred to as "heavy chain antibodies" or "HCAbs"). It is reported that camelized VHH is recombined with IgG2 and IgG3 constant regions, which contain hinges, CH2 and CH3 domains and lack CH1 domains. Camelized VHH domains have been found to bind antigen with high affinity (Desmyter et al., J. Biol. Chem., Vol. 276: 26285-90, 2001) and have high stability in solution (Ewert et al., Biochemistry, Vol. 41: 3628-36, 2002). Methods for generating antibodies with camelized heavy chains are described in, for example, U.S. Patent Publication Nos. 2005 / 0136049 and 2005 / 0037421. Alternative scaffolds can be made from human variable-like domains that are closer to the shark V-NAR scaffold and may provide a framework for long penetrating loop structures. Human heavy chain antibodies can be produced by transgenic animals expressing human immunoglobulin genes, such as those produced by UniRat TM UniAb produced in transgenic rats TM Antibody.

[0076] In certain embodiments, the binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the present invention comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) of an antibody or antibody fragment that specifically binds to a desired antigen. For example, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule of the present invention comprises a VH region and a VL region from an anti-PSMA antibody (such as any anti-PSMA antibody or fragment thereof described herein or known in the art), and the anti-CD3 binding domain comprises a VH region and a VL region from an anti-CD3 antibody (such as any anti-CD3 antibody or fragment thereof described herein or known in the art). The binding domain that specifically binds to human PSMA or human CD3 can be derived from known antibodies against these antigens or from new antibodies or antibody fragments obtained by de novo immunization methods using antigenic proteins or fragments thereof, by phage display, or other methods described herein or known in the art. The antibody from which the binding domain of the PSMA-targeted T cell engaging molecule is derived can be a monoclonal antibody, a recombinant antibody, a chimeric antibody, a human antibody, or a humanized antibody. In certain embodiments, the antibody from which the binding domain is derived is a monoclonal antibody. In these and other embodiments, the antibody is a human or humanized antibody and can be of the IgG1, IgG2, IgG3 or IgG4 type.

[0077] The first binding domain of the PSMA-targeted T cell engagement molecule used in the method of the present invention specifically binds to PSMA, preferably human PSMA. This binding domain is referred to herein as an anti-PSMA binding domain. PSMA (prostate-specific membrane antigen; also known as glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I or NAAG peptidase) is a type II membrane glycoprotein expressed primarily on prostate epithelial cells. More preferably, the first binding domain binds to PSMA on the surface of a target cell. A "target cell" can be any prokaryotic or eukaryotic cell expressing PSMA on its surface; preferably, the target cell is a cell that is part of the human or animal body, such as a specific cancer cell or tumor cell expressing PSMA. In addition, it is envisioned that the first binding domain of the PSMA-targeted T cell engagement molecule binds to human PSMA, preferably to human PSMA on the surface of a target cell. It is also envisioned that the first binding domain binds to macaque PSMA, preferably to macaque PSMA on the surface of a target cell. Exemplary amino acid sequences of mature polypeptides and extracellular domains of human PSMA and macaque PSMA are provided in Table 1 below.

[0078] Table 1. Sequences of human and macaque PSMA polypeptides

[0079]

[0080]

[0081] Examples of anti-PSMA binding domains from which the first binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the invention can be constructed or derived are described in WO 2010 / 037836, WO 2011 / 121110, WO 2017 / 134158, and WO 2020 / 206330 (all of which are hereby incorporated by reference in their entirety). Tables 2A and 2B list, respectively, the light and heavy chain variable regions of exemplary anti-human PSMA antibodies from which the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule can be derived or constructed, and the associated CDRs.

[0082] Table 2A. Exemplary anti-human PSMA antibody light chain variable region amino acid sequences

[0083]

[0084]

[0085]

[0086] Table 2B. Exemplary anti-human PSMA antibody heavy chain variable region amino acid sequences

[0087]

[0088]

[0089]

[0090]

[0091] The domain that specifically binds to human PSMA (e.g., an anti-PSMA binding domain) of the PSMA-targeted T cell engaging molecule suitable for use in the methods of the present invention may comprise one or more of the light chain CDRs (i.e., CDRLs) and / or heavy chain CDRs (i.e., CDRHs) shown in Tables 2A and 2B, respectively. For example, in some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises: a CDRL1 comprising the sequence of SEQ ID NO: 5 or SEQ ID NO: 6; a CDRL2 comprising the sequence of SEQ ID NO: 7 or SEQ ID NO: 8; a CDRL3 comprising a sequence selected from SEQ ID NOs: 9 to 13; a CDRH1 comprising a sequence of SEQ ID NO: 14 or SEQ ID NO: 15; a CDRH2 comprising a sequence selected from SEQ ID NOs: 16 to 19; and a CDRH3 comprising a sequence of SEQ ID NO: 20.

[0092] In some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engager molecule comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein: (a) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 7, and 9, respectively; (b) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 7, and 10, respectively; (c) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 7, and 11, respectively; (d) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 7, and 12, respectively; (e) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 7, and 13, respectively; (f) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 5, 8, and 9, respectively; or (g) CDRL1, CDRL2, and CDRL3 have sequences of SEQ ID NOs: 6, 8, and 9, respectively. In these and other embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engager molecule comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein: (a) CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 14, 16, and 20, respectively; (b) CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 14, 17, and 20, respectively; (c) CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 15, 18, and 20, respectively; or (d) CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 14, 19, and 20, respectively.

[0093] In certain embodiments, an anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule suitable for use in the methods of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0094] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 9, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively;

[0095] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 10, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively;

[0096] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 11, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 17 and 20, respectively;

[0097] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 12, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively;

[0098] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 13, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively;

[0099] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 11, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 15, 18 and 20, respectively;

[0100] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 7 and 11, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively;

[0101] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 5, 8 and 9, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 16 and 20, respectively; or

[0102] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 6, 8 and 9, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 14, 19 and 20, respectively. In a preferred embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule used in the method of the present invention comprises (i) a light chain variable region comprising CDRL1 having the sequence of SEQ ID NO: 5, CDRL2 having the sequence of SEQ ID NO: 8, and CDRL3 having the sequence of SEQ ID NO: 9; and (ii) a heavy chain variable region comprising CDRH1 having the sequence of SEQ ID NO: 14, CDRH2 having the sequence of SEQ ID NO: 16, and CDRH3 having the sequence of SEQ ID NO: 20.

[0103] In some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the invention comprises a heavy chain variable region from a heavy chain only antibody (such as the antibodies designated Antibodies 51 to 57 in Table 2B). In such embodiments, the anti-PSMA binding domain can comprise a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein: (a) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 158, 163, and 167, respectively; (b) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 159, 164, 168, respectively; (c) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 160, 163, and 167, respectively; (d) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 160, 165, and 167, respectively; (e) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 161, 166, and 169, respectively; or (f) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 162, 166, and 169, respectively.

[0104] In some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the present invention comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) from an antibody that specifically binds to human PSMA (such as the antibodies described herein). "Variable region" is used interchangeably herein with "variable domain" (variable region of light chain (VL), variable region of heavy chain (VH)) and refers to the region of each of the light and heavy immunoglobulin chains that is directly involved in antibody binding to an antigen. As discussed above, the variable regions of the light and heavy chains have the same general structure, and each region comprises four highly conserved framework (FR) regions connected by three CDRs. The framework regions are in a β-sheet configuration and the CDRs can form loops connecting the β-sheet structure. The CDRs in each chain maintain their three-dimensional structure through the framework regions and form an antigen binding site together with the CDRs from the other chain. Thus, in some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule used according to the methods of the present invention may comprise a light chain variable region selected from LV-01 to LV-12 (SEQ ID NOs: 21-32) (as shown in Table 2A) and / or a heavy chain variable region selected from HV-01 to HV-14 (SEQ ID NOs: 33-39 and 170-176) (as shown in Table 2B) and binding fragments, derivatives and variants of these light and heavy chain variable regions. In certain embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule may comprise only a heavy chain variable region selected from HV-08 to HV-14 (SEQ ID NOs: 170-176), which corresponds to the heavy chain variable regions of heavy chain-only antibodies 51 to 57 from Table 2B.

[0105] Each of the light chain variable regions listed in Table 2A can be combined with any of the heavy chain variable regions listed in Table 2B to form an anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention. Examples of such combinations include, but are not limited to: (i) HV-01, and any of LV-01, LV-02, LV-03, LV-04, LV-05, and LV-10; (ii) LV-03 and HV-02; (iii) LV-06 and HV-03; (iv) LV-07 and HV-04; (v) LV-08 and HV-05; (vi) LV-09 and HV-05; (vii) LV-11 and HV-06; and (viii) LV-12 and HV-07.

[0106] In certain embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 21 and a heavy chain variable region comprising the sequence of SEQ ID NO: 33. In some embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 22 and a heavy chain variable region comprising the sequence of SEQ ID NO: 33. In other embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 23 and a heavy chain variable region comprising the sequence of SEQ ID NO: 33. In still other embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 24 and a heavy chain variable region comprising the sequence of SEQ ID NO: 33. In some embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 25 and a heavy chain variable region comprising the sequence of SEQ ID NO: 33. In certain embodiments, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 23 and a heavy chain variable region comprising the sequence of SEQ ID NO: 34. In one embodiment, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 26 and a heavy chain variable region comprising the sequence of SEQ ID NO: 35. In another embodiment, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 27 and a heavy chain variable region comprising the sequence of SEQ ID NO: 36. In yet another embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 31 and a heavy chain variable region comprising the sequence of SEQ ID NO: 38.In yet another embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises the sequence of SEQ ID NO: 32, and the heavy chain variable region comprises the sequence of SEQ ID NO: 39. In some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises the sequence of SEQ ID NO: 28 or SEQ ID NO: 29, and the heavy chain variable region comprises the sequence of SEQ ID NO: 37. In a preferred embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises the sequence of SEQ ID NO: 30, and the heavy chain variable region comprises the sequence of SEQ ID NO: 33.

[0107] In certain other embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising the sequence of any one of SEQ ID NOs: 170 to 176. In some such embodiments, the anti-PSMA binding domain does not comprise a light chain variable region. In a specific embodiment, the anti-PSMA binding domain comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 170. In another specific embodiment, the anti-PSMA binding domain comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 171. In another embodiment, the anti-PSMA binding domain comprises a first heavy chain variable region having a sequence of SEQ ID NO: 170 and a second heavy chain variable region having a sequence of SEQ ID NO: 171, wherein the two heavy chain variable region sequences are optionally connected by a linker (e.g., a glycine-serine linker).

[0108] In some embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule used in accordance with the methods of the present invention comprises a light chain variable region comprising a sequence of contiguous amino acids that differ from the sequence of a light chain variable region in Table 2A (i.e., a VL selected from LV-01 to LV-12) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion, or substitution of one amino acid, and these deletions, insertions, and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The light chain variable region in some anti-PSMA binding domains comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NOs: 21 to 32 (i.e., the light chain variable region in Table 2A).

[0109] In one embodiment, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 21-32. In another embodiment, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 21-32. In yet another embodiment, the anti-PSMA binding domain of a PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 21-32.

[0110] In these and other embodiments, the anti-PSMA binding domain of the PSMA-targeted T cell engager molecule according to the present invention comprises a heavy chain variable region comprising a sequence of contiguous amino acids that differ from the sequence of a heavy chain variable region in Table 2B (i.e., a VH selected from HV-01 to HV-14) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion or substitution of one amino acid, and these deletions, insertions and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The heavy chain variable region in some anti-PSMA binding domains comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity to the amino acid sequence of SEQ ID NOs: 33 to 39 or SEQ ID NOs: 170 to 176 (i.e., the heavy chain variable region in Table 2B).

[0111] In one embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 33-39 and 170-176. In another embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 33-39 and 170-176. In yet another embodiment, the anti-PSMA binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 33-39 and 170-176.

[0112] As used herein, the term "identity" refers to the relationship between sequences as determined by comparing and comparing the sequences of two or more polypeptide molecules or two or more nucleic acid molecules. As used herein, "identity percentage" means the percentage of identical residues between amino acids or nucleotides in the molecules compared, and is calculated based on the size of the smallest molecule compared. For these calculations, the spaces (if any) in the comparison must be resolved by specific mathematical models or computer programs (i.e., "algorithms"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, AM, ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, DW, ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, AM and Griffin, HG, eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. [Journal of the Society for Industrial and Applied Mathematics] Applied Math. [Applied Mathematics] 48:1073. For example, sequence identity can be determined by standard methods commonly used to compare the similarity of amino acid positions of two polypeptides. Using a computer program such as BLAST or FASTA, two polypeptide or two polynucleotide sequences are aligned to achieve the best match of their respective residues (along the entire length of one or both sequences, or along a predetermined portion of one or both sequences).The program provides default open penalty and default gap penalty, and a scoring matrix such as PAM 250 (Dayhoff et al., see: Atlas of Protein Sequence and Structure [protein sequence and structure atlas], Volume 5, Supplement 3, 1978) or BLOSUM62 (Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA [National Academy of Sciences of the United States] 89: 10915-10919) can be used in conjunction with the computer program. For example, the percent identity can then be calculated as: the total number of identical matches multiplied by 100, then divided by the length of the longer sequence within the matching range and the sum of the number of gaps introduced into the longer sequence in order to align the two sequences. When calculating the percent identity, the compared sequences are aligned in a manner that achieves the maximum match between each sequence.

[0113] The GCG program package is a computer program that can be used to determine the percent identity, including GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, WI). The computer algorithm GAP is used to compare two polypeptides or two polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned to achieve the best match of their respective amino acids or nucleotides (as determined by the algorithm as the "match range"). A gap open penalty (calculated as 3x diagonal average, where the "diagonal average" is the average of the diagonals of the comparison matrix used; the "diagonal" is the score or value assigned to each perfect amino acid match by a particular comparison matrix) and a gap extension penalty (which is typically 1 / 10×gap open penalty) and a comparison matrix (such as PAM 250 or BLOSUM 62) are used in conjunction with the algorithm. In certain embodiments, the algorithm also uses a standard comparison matrix (for the PAM 250 comparison matrix, see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352; for the BLOSUM 62 comparison matrix, see Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919).

[0114] Recommended parameters for determining percent identity of polypeptide or nucleotide sequences using the GAP program include the following:

[0115] Algorithm: Needleman et al. 1970, J. Mol. Biol. 48:443-453;

[0116] Comparison matrix: BLOSUM 62, from Henikoff et al., 1992, supra;

[0117] Gap Penalty: 12 (but no penalty for end gaps)

[0118] Gap length penalty: 4

[0119] Similarity threshold: 0

[0120] Certain alignment schemes used to align two amino acid sequences can match only shorter regions of the two sequences, and this smaller alignment region can have a very high sequence identity, even if there is no obvious relationship between the two full-length sequences. Therefore, if necessary, the selected alignment method (GAP program) can be adjusted to align over at least 50 consecutive amino acids of the target polypeptide.

[0121] The second binding domain of the PSMA-targeted T cell engagement molecule used in the method of the present invention specifically binds to CD3, preferably human CD3. This binding domain is referred to herein as an anti-CD3 binding domain. "CD3" (cluster of differentiation 3) is a T cell co-receptor composed of four chains. In mammals, the CD3 protein complex contains a CD3γ (gamma) chain, a CD3δ (delta) chain, and two CD3ε (ipsilon) chains. These four chains associate with the T cell receptor (TCR) and the so-called ζ (zeta) chain to form a "T cell receptor complex" and generate activation signals in T lymphocytes. CD3γ (gamma), CD3δ (delta) and CD3ε (ipsilon) chains are highly related cell surface proteins of the immunoglobulin superfamily, and each contains a single extracellular immunoglobulin domain. The intracellular tail of the CD3 molecule contains a single conserved motif necessary for the signal transduction ability of the TCR, called an immunoreceptor tyrosine-based activation motif (ITAM). The CD3ε molecule is a polypeptide which, in humans, is encoded by the CD3E gene located on chromosome 11.

[0122] Redirected lysis of target cells by recruiting T cells via T cell engagement molecules that bind to CD3 on the T cell and a target protein (e.g., PSMA) on the target cell (e.g., a tumor cell) typically involves cytolytic synapse formation and the delivery of perforins and granzymes. The engaged T cells are able to continuously perform continuous target cell lysis and are not affected by immune escape mechanisms or clonal T cell differentiation that interfere with peptide antigen processing and presentation (see, e.g., WO 2007 / 042261).

[0123] In certain embodiments, the second binding domain of the PSMA-targeted T cell engaging molecule used in the methods of the present invention specifically binds to CD3 on the surface of T cells, more preferably specifically binds to human CD3 on the surface of T cells. In some embodiments, the second binding domain of the PSMA-targeted T cell engaging molecule specifically binds to CD3ε, preferably human CD3ε (e.g., human CD3ε on the surface of T cells). An exemplary amino acid sequence of the extracellular domain of human CD3ε is provided below as SEQ ID NO:40:

[0124]

[0125] Examples of anti-CD3 binding domains from which the second binding domain of the T cell engaging molecules used in the methods of the invention can be constructed or derived are described in WO 2007 / 042261 and WO 2008 / 119567 (both of which are hereby incorporated by reference in their entirety). Tables 3A and 3B list, respectively, the light and heavy chain variable regions of exemplary anti-human CD3 antibodies from which the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecules can be derived or constructed, and the associated CDRs.

[0126] Table 3A. Exemplary anti-human CD3 antibody light chain variable region amino acid sequences

[0127]

[0128]

[0129] Table 3B. Exemplary anti-human CD3 antibody heavy chain variable region amino acid sequences

[0130]

[0131]

[0132]

[0133] The domain (e.g., anti-CD3 binding domain) of the PSMA-targeted T cell engagement molecule suitable for use in the methods of the present invention that specifically binds to human CD3 may comprise one or more of the light chain CDRs (i.e., CDRLs) and / or heavy chain CDRs (i.e., CDRHs) shown in Tables 3A and 3B, respectively. For example, in some embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engagement molecule according to the present invention comprises: a CDRL1 comprising a sequence selected from SEQ ID NOs: 41 to 43 and 177; a CDRL2 comprising a sequence selected from SEQ ID NOs: 44, 45, or 178; a CDRL3 comprising a sequence selected from SEQ ID NOs: 46, 47, or 179; a CDRH1 comprising a sequence selected from SEQ ID NOs: 48 to 53 and 181; a CDRH2 comprising a sequence selected from SEQ ID NOs: 54 to 58 and 182; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 59 to 67 and 183.

[0134] In some embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engager molecule comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein: (a) CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 41, 44, and 46, respectively; (b) CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 42, 45, and 46, respectively; (c) CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 43, 44, and 47, respectively; or (d) CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 177, 178, and 179, respectively. In these and other embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engager molecule comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein: (a) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 48, 54, and 59, respectively; (b) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 49, 55, and 60, respectively; (c) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 50, 56, and 61, respectively; (d) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 51, 56, and 62, respectively; (e) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 52, 57, and 63, respectively; (f) CDRH1, CDRH2, and CDRH3 have sequences of SEQ ID NOs: 53, 58, and 64, respectively. NO:49, 54 and 64; (g) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NO:53, 58 and 65, respectively; (h) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NO:52, 57 and 66, respectively; (i) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NO:50, 56 and 67, respectively; or (j) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NO:181, 182 and 183, respectively.

[0135] In certain embodiments, an anti-CD3 binding domain of a PSMA-targeted T cell engager suitable for use in the methods of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0136] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 48, 54 and 59, respectively;

[0137] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 49, 55 and 60, respectively;

[0138] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 50, 56 and 61, respectively;

[0139] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 51, 56 and 62, respectively;

[0140] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 42, 45 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 52, 57 and 63, respectively;

[0141] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 49, 54 and 64, respectively;

[0142] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 42, 45 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 53, 58 and 65, respectively;

[0143] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 41, 44 and 46, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 52, 57 and 66, respectively;

[0144] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 43, 44 and 47, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 50, 56 and 67, respectively;

[0145] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 43, 44 and 47, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 49, 55 and 60, respectively; or

[0146] (k) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 177, 178 and 179, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 181, 182 and 183, respectively. In a preferred embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engagement molecule used in the method of the present invention comprises (i) a light chain variable region comprising CDRL1 having the sequence of SEQ ID NO: 43, CDRL2 having the sequence of SEQ ID NO: 44, and CDRL3 having the sequence of SEQ ID NO: 47; and (ii) a heavy chain variable region comprising CDRH1 having the sequence of SEQ ID NO: 49, CDRH2 having the sequence of SEQ ID NO: 55, and CDRH3 having the sequence of SEQ ID NO: 60. In another preferred embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule used in the method of the present invention comprises (i) a light chain variable region comprising CDRL1 having a sequence of SEQ ID NO: 177, CDRL2 having a sequence of SEQ ID NO: 178, and CDRL3 having a sequence of SEQ ID NO: 179; and (ii) a heavy chain variable region comprising CDRH1 having a sequence of SEQ ID NO: 181, CDRH2 having a sequence of SEQ ID NO: 182, and CDRH3 having a sequence of SEQ ID NO: 183.

[0147] The anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention may comprise a light chain variable region selected from LV-101 to LV-104 (SEQ ID NOs: 68-70 and 180) (as shown in Table 3A) and / or a heavy chain variable region selected from HV-101 to HV-110 (SEQ ID NOs: 71-79 and 184) (as shown in Table 3B) and binding fragments, derivatives and variants of these light and heavy chain variable regions. Each of the light chain variable regions listed in Table 3A can be combined with any one of the heavy chain variable regions listed in Table 3B to form an anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention. Examples of such combinations include, but are not limited to: (i) LV-101 and HV-101; (ii) LV-101 and HV-102; (iii) LV-101 and HV-103; (iv) LV-101 and HV-104; (v) LV-101 and HV-106; (vi) LV-101 and HV-108; (vii) LV-102 and HV-105; (viii) LV-102 and HV-107; (ix) LV-103 and HV-109; (x) LV-103 and HV-102; and (xi) LV-104 and HV-110.

[0148] In certain embodiments, the anti-CD3 binding domain of a PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 71. In some embodiments, the anti-CD3 binding domain of a PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 72. In other embodiments, the anti-CD3 binding domain of a PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 73. In still other embodiments, the anti-CD3 binding domain of a PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 74. In some embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 69 and a heavy chain variable region comprising the sequence of SEQ ID NO: 75. In certain embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 76. In one embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 69 and a heavy chain variable region comprising the sequence of SEQ ID NO: 77. In another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising the sequence of SEQ ID NO: 68 and a heavy chain variable region comprising the sequence of SEQ ID NO: 78. In a preferred embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the sequence of SEQ ID NO: 70, and the heavy chain variable region comprises the sequence of SEQ ID NO: 72.In another preferred embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises the sequence of SEQ ID NO: 70, and the heavy chain variable region comprises the sequence of SEQ ID NO: 79. In yet another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engagement molecule according to the present invention comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises the sequence of SEQ ID NO: 180, and the heavy chain variable region comprises the sequence of SEQ ID NO: 184.

[0149] In some embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence of contiguous amino acids that differ from the sequence of the light chain variable region in Table 3A (i.e., a VL selected from LV-101 to LV-104) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion or substitution of one amino acid, and these deletions, insertions and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The light chain variable region in some anti-CD3 binding domains comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% sequence identity with the amino acid sequence of SEQ ID NOs: 68 to 70 and 180 (i.e., the light chain variable region in Table 3A).

[0150] In one embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 68-70 and 180. In another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 68-70 and 180. In yet another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 68-70 and 180.

[0151] In these and other embodiments, the anti-CD3 binding domain of the PSMA-targeted T cell engagement molecule according to the present invention comprises a heavy chain variable region comprising a sequence of contiguous amino acids that differ from the sequence of the heavy chain variable region in Table 3B (i.e., a VH selected from HV-101 to HV-110) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion or substitution of one amino acid, and these deletions, insertions and / or substitutions cause no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The heavy chain variable region in some anti-CD3 binding domains comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% sequence identity with the amino acid sequence of SEQ ID NOs: 71 to 79 and 184 (i.e., the heavy chain variable region in Table 3B).

[0152] In one embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 71-79 and 184. In another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 71-79 and 184. In yet another embodiment, the anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 71-79 and 184.

[0153] According to certain embodiments, one or more binding domains of the PSMA-targeted T cell engaging molecule used in the methods of the present invention are in the form of scFv. In scFv, the VH region and the VL region are arranged in the order of VH-VL or VL-VH (from N-terminus to C-terminus). It is envisioned that the VH and VL regions of the first and / or second binding domains are connected via a linker, preferably a peptide linker. In one embodiment of the first and / or second binding domain, the VH region is located at the N-terminus of the linker and the VL region is located at the C-terminus of the linker. The linker is preferably a peptide linker, more preferably a short peptide linker. Examples of suitable linkers include, but are not limited to:

[0154] GGGG (SEQ ID NO: 80)

[0155] GGGGS (SEQ ID NO: 81)

[0156] ·GGGGSGGGGS(SEQ ID NO:82)

[0157] ·GGGGSGGGGSGGGGS(SEQ ID NO:83)

[0158] ·GGGGSGGGGSGGGGSGGGGS(SEQ ID NO:84)

[0159] ·GGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO:85)

[0160] ·GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO:86)

[0161] ·GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO:87)

[0162] ·GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS(SEQ ID NO:88)

[0163] ·PGGGGS(SEQ ID NO:89)

[0164] ·PGGDGS(SEQ ID NO:90)

[0165] ·SGGGGS(SEQ ID NO:91)

[0166] ·GGGGSGGGS(SEQ ID NO:92)

[0167] ·GGGGQ(SEQ ID NO:93)

[0168] In the context of the present invention, a "short" linker has between 2 and 50 amino acids, preferably between 3 and 35, between 4 and 30, between 5 and 25, between 6 and 20, or between 6 and 17 amino acids. A linker between two variable regions of a binding domain may have a different length (e.g., may be longer) than a linker between two binding domains. For example, a linker between two variable regions of one or two binding domains may have a length of between 8 and 16 amino acids, preferably between 10 and 15 amino acids, and a linker between the two binding domains may have a length of between 3 and 10 amino acids, preferably between 5 and 8 amino acids. It is further envisioned that the peptide linker is a glycine / serine linker, such as those depicted in SEQ ID NOs: 81-92. In one embodiment, the anti-PSMA binding domain and / or anti-CD3 binding domain of the PSMA-targeted T cell engaging molecule according to the present invention is a scFv, which comprises a VH region-peptide linker-VL region from the N-terminus to the C-terminus, wherein the peptide linker comprises a glycine-serine linker, such as the linker shown in SEQ ID NO: 83. In a related embodiment, the peptide linker between the anti-PSMA and anti-CD3 binding domains (e.g., scFv domains) is a linker shown in SEQ ID NO: 81 or SEQ ID NO: 91. Exemplary scFv domains of the anti-PSMA and anti-CD3 binding domains of the PSMA-targeted T cell engaging molecule suitable for use in the methods of the present invention are listed in Table 4 below.

[0169] Table 4. Exemplary single-chain variable fragment binding domains

[0170]

[0171]

[0172]

[0173]

[0174]

[0175] In certain embodiments, a PSMA-targeted T cell engaging molecule suitable for use in the methods of the invention comprises a first binding domain that specifically binds to human PSMA and has an amino acid sequence selected from any one of SEQ ID NOs: 94-106, and a second binding domain that specifically binds to human CD3 and has an amino acid sequence selected from any one of SEQ ID NOs: 107-116. In a preferred embodiment, the first binding domain (e.g., an anti-PSMA binding domain) of the PSMA-targeted T cell engaging molecule comprises the amino acid sequence of SEQ ID NO: 104. In another preferred embodiment, the second binding domain (e.g., an anti-CD3 binding domain) of the PSMA-targeted T cell engaging molecule comprises the amino acid sequence of SEQ ID NO: 116.

[0176] The PSMA-targeted T cell engaging molecules according to the present invention may comprise any anti-PSMA scFv binding domain listed in Table 4 in combination with any anti-CD3 scFv binding domain listed in Table 4. For example, in some embodiments, the PSMA-targeted T cell engaging molecules comprise an anti-PSMA scFv binding domain of Table 4 and an anti-CD3 scFv binding domain of Table 4, wherein the anti-PSMA scFv binding domain is linked to the anti-CD3 scFv binding domain via a peptide linker (such as a peptide linker described herein). In certain embodiments, the PSMA-targeted T cell engaging molecules comprise an anti-PSMA scFv binding domain, a peptide linker, and an anti-CD3 scFv binding domain in an amino to carboxyl order. In some such embodiments, the peptide linker comprises the sequence of SEQ ID NO: 81 or SEQ ID NO: 91.

[0177] The PSMA-targeted T cell engaging molecules according to the present invention may also comprise other domains, which, for example, may modulate the pharmacokinetic characteristics of the molecule. For example, the PSMA-targeted T cell engaging molecules may further comprise an immunoglobulin Fc domain, a domain derived from serum albumin (e.g., human serum albumin), or an albumin binding domain (e.g., comprising a human albumin binding peptide), and / or conjugated to a polyethylene glycol chain to extend the serum half-life of the T cell engaging molecule. In certain embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention further comprise one or more immunoglobulin Fc domains. Each immunoglobulin Fc domain may comprise one or more Fc monomers. Each "Fc monomer" typically comprises at least a CH2 domain and a CH3 domain from an immunoglobulin molecule. The Fc monomer may comprise a CH2 and CH3 domain from an IgG1, IgG2, IgG3, or IgG4 immunoglobulin. For example, the CH2 domain comprises amino acids 231 to 340 of an IgG1 immunoglobulin, and the CH3 domain comprises amino acids 341 to 446 of an IgG1 immunoglobulin, wherein the amino acid numbering is according to the EU numbering system described in Edelman et al., Proc. Natl. Acad. USA, Vol. 63: 78-85 (1969) and Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health Publication No. 91-3242, Bethesda, Maryland (MD) (1991). The boundaries of the CH2 and CH3 domains may vary slightly from one IgG subtype to another, but the CH2 and CH3 domains in IgG2, IgG3, and IgG4 can be determined by alignment with the CH2 and CH3 domains in IgG1.

[0178] In some embodiments, Fc monomers may include an immunoglobulin hinge region or a portion thereof. An immunoglobulin hinge region is typically a region defined by amino acids 216 to 231 (according to the EU numbering system) of an IgG immunoglobulin. In certain embodiments, an Fc monomer includes a hinge region from an IgG1 immunoglobulin or a portion thereof. In some such embodiments, an IgG1 hinge region includes an amino acid sequence DKTHTCPPCP (SEQ ID NO: 117) or EPKSCDKTHTCPPCP (SEQ ID NO: 118). In other embodiments, an Fc monomer includes an IgG2 hinge region with a sequence ERKCCVECPPCP (SEQ ID NO: 119), an IgG3 hinge region with a sequence ELKTPLDTTHTCPRCP (SEQ ID NO: 120), an EPKSCDTPPPCPRCP (SEQ ID NO: 121) or an ELKTPLGDTTHTCPRCP (SEQ ID NO: 122), or an IgG4 hinge region with a sequence ESKYGPPCPSCP (SEQ ID NO: 123). In certain embodiments, an Fc monomer comprises, in amino to carboxyl order, an immunoglobulin hinge region, an immunoglobulin CH2 domain, and an immunoglobulin CH3 domain.

[0179] In certain embodiments, the PSMA-targeted T cell engaging molecule comprises an Fc domain having one Fc monomer. In alternative embodiments, the PSMA-targeted T cell engaging molecule comprises a domain having two or more Fc monomers. For example, in one embodiment, the PSMA-targeted T cell engaging molecule used in the method of the present invention comprises an Fc domain having two Fc monomers. The two Fc monomers can be present on separate polypeptide chains and associate to form a dimer, for example, via non-covalent interactions and / or disulfide bonds (e.g., between cysteine ​​residues in the hinge region of the Fc monomer). In a preferred embodiment, the two Fc monomers are fused to each other via a peptide linker, preferably a linker of sufficient length to allow the Fc monomers to associate and form intrachain dimers. The fusion of two Fc monomers to form a single polypeptide chain is referred to herein as a single-chain Fc domain (scFc domain), and is described in more detail below.

[0180] The peptide linker by which the Fc monomers are fused to each other to form a single-chain Fc domain preferably comprises at least 25 amino acid residues (e.g., 25, 26, 27, 28, 29, 30 or more). More preferably, this peptide linker comprises at least 30 amino acid residues (e.g., 30, 31, 32, 33, 34, 35 or more). In some embodiments, the linker comprises up to 40 amino acid residues, more preferably up to 35 amino acid residues, and even more preferably exactly 30 amino acid residues. In certain embodiments, the peptide linker comprises glycine-serine residues, such as repeats of the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 81). In such embodiments, the peptide linker comprises (Gly 4 Ser) x , wherein x is an integer of 5 or greater (e.g., 6, 7 or 8). Preferably, the integer is 6 or 7, more preferably the integer is 6. In a specific embodiment, the peptide linker used to connect the two Fc monomers to form a single-chain Fc domain comprises the sequence of SEQ ID NO: 86.

[0181] Relative to native CH2 or CH3 immunoglobulin amino acid sequence, Fc monomer can contain one or more amino acid substitutions, for example, to regulate effector function, change glycosylation or enhance stability. For example, in one embodiment, the glycosylation site at this position in the CH2 domain is removed by replacing the asparagine residue at amino acid position 297 (according to EU numbering) with different amino acids. In some embodiments, N297G substitution is preferred. The mutation for enhancing stability includes replacing one or more amino acids in CH2 and / or CH3 domains with cysteine ​​residues to promote the formation of disulfide bonds. Preferably, specific residues are replaced by cysteine ​​so that they preferentially form disulfide bonds with each other, thereby limiting or preventing disulfide bond confusion. Preferred pairs include but are not limited to A287C and L306C, V259C and L306C, R292C and V302C and V323C and I332C, wherein the amino acid position is numbered according to the EU numbering system. In a specific embodiment, one or more Fc monomers incorporated into the Fc domain of a PSMA-targeted T cell engager molecule comprises N297G, R292C, and V302C substitutions, wherein amino acid positions are numbered according to the EU numbering system.

[0182] In certain preferred embodiments, the PSMA-targeted T cell engaging molecule used in the methods of the present invention comprises an Fc domain that is a single-chain Fc domain. Thus, in certain such embodiments, the Fc domain comprises two Fc monomers, each monomer comprising an immunoglobulin hinge region, an immunoglobulin CH2 domain, and an immunoglobulin CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker as described herein. Exemplary amino acid sequences of Fc monomers and single-chain Fc (scFc) domains are provided in Table 5 below. In some embodiments, each Fc monomer of the Fc domain has an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 124-131. In other embodiments, each Fc monomer of the Fc domain has an amino acid sequence selected from SEQ ID NOs: 124-131. In a preferred embodiment, each Fc monomer of the Fc domain comprises an amino acid sequence of SEQ ID NO: 124. In another preferred embodiment, each Fc monomer of the Fc domain comprises an amino acid sequence of SEQ ID NO: 125.

[0183] Table 5. Exemplary Fc monomers and single-chain Fc domains

[0184]

[0185]

[0186]

[0187]

[0188] The Fc domain of the PSMA-targeted T cell engaging molecule used in the method of the present invention may be any scFc domain listed in Table 5 or a variant of these scFc domains. In one embodiment, the PSMA-targeted T cell engaging molecule according to the present invention comprises an Fc domain comprising an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOs: 132-139. In another embodiment, the PSMA-targeted T cell engaging molecule according to the present invention comprises an Fc domain comprising an amino acid sequence selected from SEQ ID NOs: 132-139. In a preferred embodiment, the PSMA-targeted T cell engaging molecule according to the present invention comprises an Fc domain comprising an amino acid sequence of SEQ ID NO: 132. In another preferred embodiment, the PSMA-targeted T cell engaging molecule according to the present invention comprises an Fc domain comprising an amino acid sequence of SEQ ID NO: 133.

[0189] In certain embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the invention comprise, in amino to carboxyl order:

[0190] (i) a first domain that specifically binds to human PSMA, the first domain comprising a first immunoglobulin heavy chain variable region (VH1) and a first immunoglobulin light chain variable region (VL1);

[0191] (ii) a second domain that specifically binds to human CD3, the second domain comprising a second immunoglobulin heavy chain variable region (VH2) and a second immunoglobulin light chain variable region (VL2); and

[0192] (iii) An Fc domain comprising two Fc monomers.

[0193] In such embodiments, each Fc monomer may comprise an immunoglobulin hinge region, a CH2 domain, and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker, such as any of the peptide linkers described herein.

[0194] In some embodiments, the PSMA-targeted T cell engaging molecule comprises, in amino to carboxyl order:

[0195] (i) a first domain that specifically binds to human PSMA, comprising VH1 and VL1, wherein VH1 comprises a CDRH1 having a sequence of SEQ ID NO: 14 or SEQ ID NO: 15, a CDRH2 having a sequence selected from SEQ ID NOs: 16-19, and a CDRH3 having a sequence of SEQ ID NO: 20, and wherein VL1 comprises a CDRL1 having a sequence selected from SEQ ID NO: 5 or SEQ ID NO: 6, a CDRL2 having a sequence of SEQ ID NO: 7 or SEQ ID NO: 8, and a CDRL3 having a sequence selected from SEQ ID NOs: 9-13;

[0196] (ii) a second domain that specifically binds to human CD3, comprising VH2 and VL2, wherein the VH2 comprises a CDRH1 having a sequence selected from the group consisting of SEQ ID NOs: 48-53, a CDRH2 having a sequence selected from the group consisting of SEQ ID NOs: 54-58, and a CDRH3 having a sequence selected from the group consisting of SEQ ID NOs: 59-67, and the VL2 comprises a CDRL1 having a sequence selected from the group consisting of SEQ ID NOs: 41-43, a CDRL2 having a sequence of SEQ ID NOs: 44 or SEQ ID NOs: 45, and a CDRL3 having a sequence of SEQ ID NOs: 46 or SEQ ID NOs: 47; and

[0197] (iii) an Fc domain comprising two Fc monomers, each monomer comprising an immunoglobulin hinge region, a CH2 domain, and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker. In such embodiments, VH1 comprises a sequence selected from SEQ ID NOs: 33-39, and VL1 comprises a sequence selected from SEQ ID NOs: 21-32. In these and other embodiments, VH2 comprises a sequence selected from SEQ ID NOs: 71-79, and VL2 comprises a sequence selected from SEQ ID NOs: 68-70. In one embodiment, VH1 comprises a sequence of SEQ ID NO: 33, and VL1 comprises a sequence of SEQ ID NO: 30. In a related embodiment, VH2 comprises a sequence of SEQ ID NO: 72, and VL2 comprises a sequence of SEQ ID NO: 70.

[0198] In a preferred embodiment, the PSMA-targeted T cell engaging molecule comprises, in order from amino to carboxyl:

[0199] (i) a first domain that specifically binds to human PSMA, comprising VH1 and VL1, wherein VH1 comprises CDRH1 having a sequence of SEQ ID NO: 14, CDRH2 having a sequence of SEQ ID NO: 16, and CDRH3 having a sequence of SEQ ID NO: 20, and VL1 comprises CDRL1 having a sequence of SEQ ID NO: 5, CDRL2 having a sequence of SEQ ID NO: 8, and CDRL3 having a sequence of SEQ ID NO: 9;

[0200] (ii) a second domain that specifically binds to human CD3, comprising VH2 and VL2, wherein VH2 comprises CDRH1 having a sequence of SEQ ID NO: 49, CDRH2 having a sequence of SEQ ID NO: 55, and CDRH3 having a sequence of SEQ ID NO: 60, and VL2 comprises CDRL1 having a sequence of SEQ ID NO: 43, CDRL2 having a sequence of SEQ ID NO: 44, and CDRL3 having a sequence of SEQ ID NO: 47; and

[0201] (iii) An Fc domain comprising two Fc monomers, each monomer comprising an immunoglobulin hinge region, a CH2 domain and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker.

[0202] In certain embodiments, a peptide linker such as those described herein connects the first domain to the second domain and / or connects the second domain to the Fc domain. Thus, in some embodiments, a PSMA-targeted T cell engaging molecule according to the present invention comprises, in amino to carboxyl order:

[0203] (i) a first domain that specifically binds to human PSMA;

[0204] (ii) a first peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 81-83 and 91;

[0205] (iii) a second domain that specifically binds to human CD3;

[0206] (iv) a second peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-83 and 89-91;

[0207] (v) a first Fc monomer;

[0208] (vi) a third peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-88; and

[0209] (vii) A second Fc monomer.

[0210] In certain embodiments, a PSMA-targeted T cell engaging molecule according to the present invention comprises, in amino to carboxyl order:

[0211] (i) a first domain (eg, an anti-PSMA binding domain) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 94-106;

[0212] (ii) a first peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 81-83 and 91;

[0213] (iii) a second domain (eg, an anti-CD3 binding domain) having an amino acid sequence selected from SEQ ID NOs: 107-116;

[0214] (iv) a second peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-83 and 89-91;

[0215] (v) a first Fc monomer having an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-131;

[0216] (vi) a third peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NOs: 85-88; and

[0217] (vii) a second Fc monomer having an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-131.

[0218] In a preferred embodiment, the PSMA-targeted T cell engaging molecule according to the present invention comprises, in order from amino to carboxyl groups:

[0219] (i) a first domain (eg, an anti-PSMA binding domain) having an amino acid sequence of SEQ ID NO: 104;

[0220] (ii) a first peptide linker having an amino acid sequence of SEQ ID NO: 81 or SEQ ID NO: 91;

[0221] (iii) a second domain (eg, an anti-CD3 binding domain) having an amino acid sequence of SEQ ID NO: 116;

[0222] (iv) a second peptide linker having an amino acid sequence of SEQ ID NO: 80 or SEQ ID NO: 81;

[0223] (v) a first Fc monomer having an amino acid sequence of SEQ ID NO: 124;

[0224] (vi) a third peptide linker having an amino acid sequence of SEQ ID NO: 86 or SEQ ID NO: 87; and

[0225] (vii) a second Fc monomer having the amino acid sequence of SEQ ID NO: 124.

[0226] In certain embodiments, the PSMA-targeted T cell engaging molecule used in the methods of the present invention is a single-chain polypeptide or a single-chain fusion protein. As used herein, "single-chain polypeptide" or "single-chain fusion protein" refers to a molecule consisting of only one polypeptide chain, i.e., all domains in the T cell engaging molecule are optionally linked together via a peptide linker to form a single polypeptide chain. In the context of the present invention, an example of such a single-chain polypeptide or a single-chain fusion protein is a single-chain polypeptide comprising a PSMA scFv domain, a first peptide linker, an anti-CD3 scFv domain, a second peptide linker, and a scFc domain in the order of amino to carboxyl. Table 6 below lists exemplary PSMA-targeted T cell engaging single-chain polypeptides or single-chain fusion proteins that can be used in the methods of the present invention. Other PSMA-targeted T cell engaging single-chain polypeptides or single-chain fusion proteins suitable for use in the methods of the present invention are described in WO 2017 / 134158, which is hereby incorporated by reference in its entirety.

[0227] Table 6. Exemplary PSMA-targeted T cell-engaging single-chain polypeptides

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238] In certain embodiments, the PSMA-targeted T cell engaging molecule administered to a patient according to the methods of the present invention comprises an amino acid sequence selected from SEQ ID NOs: 140-157. In one embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence of SEQ ID NO: 141. In another embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence of SEQ ID NO: 144. In yet another embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence of SEQ ID NO: 147. In yet another embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence of SEQ ID NO: 150. In a preferred embodiment, the PSMA-targeted T cell engaging molecule used in the methods of the present invention comprises an amino acid sequence of SEQ ID NO: 140 (e.g., icapatumumab).

[0239] The PSMA-targeted T cell engaging molecule used in the method of the present invention may be a variant of the single-chain polypeptide shown in Table 6, and comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 140-157. In one embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NO: 140-157. In another embodiment, the PSMA-targeted T cell engaging molecule comprises an amino acid sequence that is at least 98% identical to an amino acid sequence selected from SEQ ID NO: 140-157. In certain embodiments, the sequence variability occurs in the peptide linker region and / or the single-chain Fc domain.

[0240] In other embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention comprise two or more polypeptide chains. For example, in some embodiments, the PSMA-targeted T cell engaging molecules comprise three polypeptide chains, wherein the first polypeptide is a light chain from an anti-CD3 antibody, the second polypeptide is a heavy chain from an anti-CD3 antibody, and the third polypeptide is a modified heavy chain comprising a heavy chain variable region from an anti-PSMA heavy chain-only antibody. Such three-polypeptide chain T cell engaging molecules are described in WO 2020 / 206330, which is hereby incorporated by reference in its entirety. Therefore, in certain embodiments, the PSMA-targeted T cell engaging molecules used in the methods of the present invention comprise:

[0241] (a) a first polypeptide comprising or consisting of a light chain polypeptide from an anti-CD3 antibody;

[0242] (b) a second polypeptide comprising or consisting of a heavy chain polypeptide from an anti-CD3 antibody; and

[0243] (c) a third polypeptide comprising a heavy chain variable region from an anti-PSMA antibody fused to a heavy chain immunoglobulin constant region.

[0244] Exemplary polypeptide sequences for constructing multi-chain PSMA-targeted T cell engaging molecules are listed in Table 7. In some such embodiments, the first polypeptide comprises the sequence of SEQ ID NO: 185, the second polypeptide comprises the sequence of SEQ ID NO: 186, and the third polypeptide comprises a sequence selected from SEQ ID NO: 187-192. In a specific embodiment, the PSMA-targeted T cell engaging molecule employed in the methods of the present invention comprises a first polypeptide having a sequence of SEQ ID NO: 185, a second polypeptide having a sequence of SEQ ID NO: 186, and a third polypeptide having a sequence of SEQ ID NO: 187. In another specific embodiment, the PSMA-targeted T cell engaging molecule employed in the methods of the present invention comprises a first polypeptide having a sequence of SEQ ID NO: 185, a second polypeptide having a sequence of SEQ ID NO: 186, and a third polypeptide having a sequence of SEQ ID NO: 191. In yet another specific embodiment, the PSMA-targeted T cell engaging molecule used in the method of the present invention comprises a first polypeptide having a sequence of SEQ ID NO: 185, a second polypeptide having a sequence of SEQ ID NO: 186, and a third polypeptide having a sequence of SEQ ID NO: 192.

[0245] Table 7. Exemplary polypeptide chains of multi-chain T cell engaging molecules

[0246]

[0247]

[0248]

[0249] In certain embodiments, the methods of the invention comprise administering one or more cycles of an anti-androgen compound in combination with a PSMA-targeted T cell engager to a patient in need of treatment for prostate cancer, wherein the first cycle is about 28 days and comprises:

[0250] administering a first dose (e.g., a priming dose) of about 30 μg to about 300 μg of the T cell engaging molecule by continuous intravenous infusion on days 1 to 3 of the cycle;

[0251] administering a therapeutic dose of about 90 μg to about 1.8 mg of the T cell engager molecule by intravenous push on days 8 and 22 of the cycle; and

[0252] The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

[0253] In some embodiments of the methods of the invention, the first period is about 28 days and comprises:

[0254] A first dose (eg, a priming dose) of about 90 μg of the T cell engaging molecule is administered by continuous intravenous infusion on days 1 to 3 of the cycle;

[0255] administering a therapeutic dose of about 150 μg or about 300 μg of the T cell engager molecule by intravenous push on days 8 and 22 of the cycle; and

[0256] The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

[0257] In any of the foregoing embodiments, the PSMA-targeted T cell engager can be icapatumumab, which is a single-chain polypeptide comprising the sequence of SEQ ID NO: 140, and the anti-androgen compound can be enzalutamide, abiraterone, abiraterone acetate, darolutamide, or apalutamide. For example, in some embodiments, the methods of the present invention comprise administering one or more cycles of enzalutamide and icapatumumab in combination to a patient in need of treatment for prostate cancer, wherein the first cycle is about 28 days and comprises:

[0258] A first dose (eg, priming dose) of about 90 μg of icapatumumab is administered by continuous intravenous infusion on days 1 to 3 of the menstrual cycle;

[0259] administering a therapeutic dose of about 150 μg or about 300 μg of icapatumumab by intravenous push on days 8 and 22 of the cycle; and

[0260] Enzalutamide is administered orally once daily at a dose of about 160 mg on each of days 15 to 28 of the cycle.

[0261] In other embodiments, the methods of the invention comprise administering one or more cycles of abiraterone or abiraterone acetate in combination with icapatumumab to a patient in need of treatment for prostate cancer, wherein the first cycle is about 28 days and comprises:

[0262] A first dose (eg, priming dose) of about 90 μg of icapatumumab is administered by continuous intravenous infusion on days 1 to 3 of the menstrual cycle;

[0263] administering a therapeutic dose of about 150 μg or about 300 μg of icapatumumab by intravenous push on days 8 and 22 of the cycle; and

[0264] Abiraterone or abiraterone acetate is administered orally once daily at a dose of about 1,000 mg on each of days 15 to 28 of the cycle.

[0265] In certain embodiments, the methods of the present invention comprise administering one or more cycles of darolutamide in combination with ecapastuzumab to a patient in need of treatment for prostate cancer, wherein the first cycle is about 28 days and comprises:

[0266] A first dose (eg, priming dose) of about 90 μg of icapatumumab is administered by continuous intravenous infusion on days 1 to 3 of the menstrual cycle;

[0267] administering a therapeutic dose of about 150 μg or about 300 μg of icapatumumab by intravenous push on days 8 and 22 of the cycle; and

[0268] Darolutamide is administered orally at a dose of about 600 mg twice daily on each of days 15 to 28 of the cycle.

[0269] In certain other embodiments, the methods of the invention comprise administering one or more cycles of apalutamide in combination with ecaptuzumab to a patient in need of treatment for prostate cancer, wherein the first cycle is about 28 days and comprises:

[0270] A first dose (eg, priming dose) of about 90 μg of icapatumumab is administered by continuous intravenous infusion on days 1 to 3 of the menstrual cycle;

[0271] administering a therapeutic dose of about 150 μg or about 300 μg of icapatumumab by intravenous push on days 8 and 22 of the cycle; and

[0272] Apalutamide is administered orally once daily at a dose of about 240 mg on each of days 15 to 28 of the cycle.

[0273] In any of the foregoing embodiments, the methods may further comprise administering to the patient a maintenance cycle, wherein the maintenance cycle comprises administering a therapeutic dose of a PSMA-targeted T cell engager (e.g., icapatumumab) by intravenous bolus once every 14 days (Q2W) and orally administering an anti-androgen compound once or twice daily on each day of the cycle.

[0274] In certain embodiments of the methods of the present invention, one or more premedications may be administered to the patient prior to administering the first dose of the PSMA-targeted T cell engaging molecule in the first cycle. In some embodiments, the premedication is administered to the patient prior to administering each dose of the PSMA-targeted T cell engaging molecule in the first cycle. The premedication may also be administered to the patient prior to administering one or more doses of the PSMA-targeted T cell engaging molecule in one or more maintenance cycles. In some embodiments, the premedication is administered to the patient prior to administering one or more doses only during the first cycle, and the premedication is not administered to the patient prior to administering any dose of the PSMA-targeted T cell engaging molecule in subsequent treatment cycles (e.g., maintenance cycles). It is contemplated that in this particular context, "before..." means within 72 hours, 48 ​​hours, 36 hours, 24 hours, 18 hours, 16 hours, 12 hours, 6 hours, 5 hours, 4 hours, or 3 hours, preferably within 120, 90, 60, or 30 minutes, before the start of administration of the PSMA-targeted T cell engaging molecule. Depending on the type of premedication used and its route of administration, the premedication can be administered, for example, 30-120 or 30-60 minutes prior to the start of administration of the PSMA-targeted T cell engager. Premedication can be administered, for example, to prevent or reduce the severity of infusion-related reactions and / or to prevent or reduce the severity of cytokine release syndrome or its symptoms.

[0275] In some embodiments, the premedication is an antihistamine. The antihistamine can be administered orally or intravenously, and can be administered at a dose equivalent to diphenhydramine 50 mg iv. Suitable antihistamines that may be administered as a premedication include, but are not limited to, oral, parenteral or rectal antihistamines such as: azatadine (maximum dose, e.g., 4 mg / day), brompheniramine (maximum dose, e.g., 30 mg / day), cetirizine (maximum dose, e.g., 15 mg / day), chlorpheniramine (maximum dose, e.g., 30 mg / day), clematine (maximum dose, e.g., 10 mg / day), cyproheptadine (maximum dose, e.g., 15 mg / day), desloratadine (maximum dose, e.g., 7 mg / day), dexlorpheniramine (maximum dose, e.g., 15 mg / day), diphenhydramine (maximum dose, e.g., 350 mg / day), doxylamine (maximum dose, e.g., 180 mg / day), fexofenadine (maximum dose, e.g., 200 mg / day), loratadine (maximum dose, e.g., 15 mg / day) and phenindamine (maximum dose, e.g., 180 mg / day).

[0276] In other embodiments, the pre-medication is a glucocorticoid. Glucocorticoid is a class of corticosteroids, which is a class of steroid hormones. Glucocorticoids are corticosteroids that bind to glucocorticoid receptors. Less common synonyms are glucocorticoids. Cortisol (called hydrocortisone when used as a drug) is the most important human glucocorticoid. A variety of synthetic glucocorticoids (some far more effective than cortisol) have been created for therapeutic use. Cortisol is a comparative standard for the effectiveness of glucocorticoids. An example of a commonly prescribed alternative steroid equivalent can be prednisone (5mg) = cortisone (25mg) = dexamethasone (0.75mg) = hydrocortisone (20mg) = methylprednisolone (4mg). These doses indicate the equivalent pharmacological doses of systemic glucocorticoids. Glucocorticoids can be administered orally or intravenously, and can be administered at a dose equivalent to 4-20mg dexamethasone iv. (Equivalent refers to the effectiveness of glucocorticoids). The dose of glucocorticoid can be the same at each administration (i.e., at each administration of glucocorticoid premedication). Alternatively, if there are no or minimal signs of infusion reactions and / or CRS symptoms after the previous administration of the PSMA-targeted T cell engagement molecule, the dose of glucocorticoid can be reduced in subsequent administrations, for example, by 50% of the previous dose. In certain embodiments, glucocorticoids are administered as premedication only during the first cycle and are not administered in subsequent treatment cycles (e.g., maintenance cycles).

[0277] Examples of glucocorticoids to be used as premedications include, but are not limited to, cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, beclomethasone, budesonide, triamcinolone, cloprednol, deflazacort, fluocortolone, cortisol, paramethasone, fluticasone, fluticasone propionate, triamcinolone acetonide, and combinations thereof and / or pharmaceutically acceptable derivatives. Different glucocorticoids may be used alone or in combination. Dexamethasone, prednisone, and prednisolone are preferred glucocorticoids used as premedications according to the methods of the present invention. In certain embodiments of the methods of the present invention, the glucocorticoid administered to the patient prior to administering one or more (or all) doses of the PSMA-targeted T cell engaging molecule during the first cycle and / or maintenance cycle is dexamethasone. Dexamethasone may be administered at a dose of about 4-20 mg, 6-18 mg, 8-16 mg, about 16 mg, or about 8 mg per administration. In some embodiments of the methods of the present invention, dexamethasone is administered to the patient prior to administration of each dose of the PSMA-targeted T cell engaging molecule during the first cycle. In these and other embodiments, dexamethasone is orally administered to the patient at a dose of about 8 mg about 6-16 hours before administration of each dose of the PSMA-targeted T cell engaging molecule during the first cycle. In other embodiments, dexamethasone is administered intravenously to the patient within one hour before administration of each dose of the PSMA-targeted T cell engaging molecule during the first cycle at a dose of about 8 mg. In yet other embodiments, the methods of the present invention further include orally administering an 8 mg dose of dexamethasone (or an equivalent dose of other glucocorticoids) to the patient about 6-16 hours before administration of each dose of the PSMA-targeted T cell engaging molecule during the first cycle, and administering an 8 mg dose of dexamethasone (or an equivalent dose of other glucocorticoids) to the patient intravenously within one hour before administration of each dose of the PSMA-targeted T cell engaging molecule.

[0278] Patients can be treated according to the methods of the present invention for a set treatment period. A "treatment period" begins with the administration of a first dose of a PSMA-targeted T cell engaging molecule in a first cycle or initiation cycle, and ends with the administration of a final dose of a PSMA-targeted T cell engaging molecule and / or an anti-androgen compound in a maintenance cycle. The treatment period can be from about 3 months to about 36 months, from about 12 months to about 24 months, or from about 6 months to about 12 months. For example, the treatment period can be about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 18 months, about 21 months, about 24 months, about 27 months, about 30 months, about 33 months, or about 36 months. In some embodiments, the treatment period is about 6 months. In other embodiments, the treatment period is about 9 months. In yet other embodiments, the treatment period is about 12 months. The treatment period for each patient can be adjusted according to the patient's response to treatment. In a specific embodiment, a patient is treated according to the methods of the invention until the patient achieves a complete response or until no evidence of prostate cancer is otherwise detectable in the patient.

[0279] In certain embodiments, the patient treated according to the method of the present invention may have failed or been intolerant to one or more previous prostate cancer therapies (such as chemotherapy, radiotherapy, androgen deprivation therapy or radioligand therapy). As used herein, if the patient's cancer progresses after the standard treatment regimen (for example, the size of the prostate tumor increases; the presence, quantity or size of metastatic lesions increases; the blood level of PSA increases), it is considered that the patient has failed treatment. If the patient cannot tolerate a certain therapy, or the therapy is contraindicated to the patient, it is also considered that the patient has failed treatment. As used herein, if the patient's cancer does not respond or loses the initial response after continuous administration of therapy, it is considered that the patient is refractory or resistant to the therapy. As used herein, if the signs and symptoms of prostate cancer (such as blood PSA levels increase, cancer cells in the prostate, metastatic lesions, etc.) reappear after the patient's condition is relieved, it is considered that the patient relapses after therapy.

[0280] In certain embodiments, the patient to be treated according to the methods of the present invention has failed or is intolerant to one or more chemotherapy regimens. In a related embodiment, the patient to be treated according to the methods of the present invention is refractory or resistant to one or more chemotherapy regimens. Standard chemotherapy regimens for treating prostate cancer typically include regimens of mitoxantrone, estramustine, carboplatin, oxaliplatin, cisplatin, and taxane chemotherapy regimens, such as regimens of docetaxel, cabazitaxel, or paclitaxel. In one embodiment, the patient to be treated according to the methods of the present invention has failed or is intolerant, refractory, or resistant to one or more taxane chemotherapy regimens. In another embodiment, the patient to be treated according to the methods of the present invention has failed or is intolerant, refractory, or resistant to two or more taxane chemotherapy regimens. In such embodiments, the patient may have failed or is intolerant, refractory, or resistant to a docetaxel regimen and / or a cabazitaxel regimen.

[0281] In other embodiments, the patient to be treated according to the methods of the invention has failed or is intolerant, refractory or resistant to one or more androgen deprivation therapies. Androgen deprivation therapies include, but are not limited to, surgical castration (e.g., bilateral orchiectomy), chemical castration with an LHRH agonist or antagonist (e.g., leuprolide, goserelin, triptorelin, histrelin or degarelix), or treatment with an anti-androgen compound such as an androgen biosynthesis inhibitor (e.g., abiraterone, ketoconazole) or an androgen receptor antagonist (e.g., flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide or darolutamide). In certain embodiments, the patient has failed or is intolerant, resistant or refractory to at least one previous anti-androgen compound (e.g., abiraterone, ketoconazole, flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide or darolutamide). In related embodiments, the patient has failed or is intolerant, resistant or refractory to one or more anti-androgen compounds selected from abiraterone, enzalutamide, apalutamide and darolutamide. In such embodiments where the patient has failed or is intolerant, resistant or refractory to treatment with a previous anti-androgen compound, the anti-androgen compound administered to the patient according to the combination treatment methods of the present invention is preferably an anti-androgen compound different from the anti-androgen compound previously received by the patient.

[0282] In certain other embodiments, the patient to be treated according to the methods of the invention has failed or is intolerant, refractory, or resistant to radioligand therapy. Radioligand therapy is an agent comprising a radionuclide or radioisotope covalently attached to a targeting ligand (e.g., an antibody, peptide, or small molecule) that specifically binds to a protein on the surface of a cancer cell. In some embodiments, the radioligand therapy to which the patient is refractory or resistant is a PSMA-targeted radioligand therapy, such as one comprising a radionuclide (e.g., Lutetium-177 ( 177 Lu), actinium-225( 225 Ac), Yttrium-90( 90 Y) or iodine-131( 131 I)), which is attached to a PSMA targeting ligand, such as PSMA-11, PSMA-617, PSMA-1007, an anti-PSMA antibody (e.g., humanized antibody J591) or a binding fragment thereof, or MIP-1095 ((S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)glutaric acid). PSMA targeted radiation therapy includes, but is not limited to 177 Lu-PSMA-617, 225 Ac-PSMA-617, 225 Ac-huJ591, 177 Lu-huJ591, 90 Y-huJ591 and 131 I-MIP-1095. Other PSMA-targeted radiation therapies are described in Czerwinksa et al., Molecules [molecules], Vol. 25: 1743, 2020, which is hereby incorporated by reference in its entirety. In one embodiment, the patient to be treated according to the method of the present invention has been treated with 177 In another embodiment, the patient to be treated according to the method of the present invention has failed or is intolerant, refractory or resistant to Lu-PSMA-617 radioligand therapy. 225 Patients who have failed or are intolerant, refractory, or resistant to Ac-PSMA-617 radioligand therapy.

[0283] The PSMA-targeted T cell engaging molecules used in the methods of the present invention can be prepared by various conventional techniques. For example, the PSMA-targeted T cell engaging molecules described herein can be produced by a recombinant expression system using any technique known in the art. See, for example, Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.) Plenum Press, New York (1980); and Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988).

[0284] PSMA-targeted T cell engaging molecules or their components (e.g., Fv fragments, Fc monomers) can be expressed in hybridoma cell lines or cell lines other than hybridomas. Expression vectors or constructs encoding T cell engaging molecules can be used to transform mammalian, insect or microbial host cells. The term "vector" refers to any molecule or entity (e.g., nucleic acid, plasmid, phage or virus) used to transfer protein coding information to a host cell. Examples of vectors include, but are not limited to, plasmids, viral vectors, non-episomal mammalian vectors and expression vectors (e.g., recombinant expression vectors). As used herein, the term "expression vector" or "expression construct" refers to a recombinant nucleic acid molecule containing a desired coding sequence and appropriate nucleic acid control sequences necessary for expressing an operably linked coding sequence in a specific host cell. Expression vectors may include, but are not limited to, sequences that affect or control transcription, translation, and (if introns are present) RNA splicing of the coding region operably linked thereto. Nucleic acid sequences necessary for expression in prokaryotes include promoters, optionally operator sequences, ribosome binding sites, and possible other sequences. It is known that eukaryotic cells utilize promoters, enhancers, and terminators as well as polyadenylation signals. A secretory signal peptide sequence may also be optionally encoded by an expression vector, operably linked to the coding sequence of interest, so that the expressed polypeptide can be secreted by the recombinant host cell, if desired, so as to more easily separate the polypeptide of interest from the cell.

[0285] The recombinant expression vector or construct will typically contain a nucleic acid molecule encoding a polypeptide comprising one or more of the following: one or more CDRs provided herein; a light chain constant region; a light chain variable region; a heavy chain constant region (e.g., CH1, CH2, and / or CH3); a heavy chain variable region; a hinge region, an Fc domain, and / or another scaffold portion of an anti-PSMA antibody or an anti-CD3 antibody. These nucleic acid sequences are inserted into an appropriate expression vector using standard ligation techniques. In embodiments where the T cell engagement molecule is a single-chain polypeptide or a single-chain fusion protein, the nucleic acid contained in the recombinant expression vector will typically encode a full-length single-chain polypeptide (e.g., a full-length single-chain fusion protein). A vector that is functional in the particular host cell employed is typically selected (i.e., the vector is compatible with the host cell machinery, thereby allowing amplification and / or expression of the gene to occur). In some embodiments, the vector used employs a protein fragment complementation assay using a protein reporter (such as dihydrofolate reductase) (see, e.g., U.S. Pat. No. 6,270,964, which is hereby incorporated by reference). Suitable expression vectors can be purchased from, for example, Invitrogen Life Technologies or BD Biosciences (formerly "Clontech"). Other useful vectors for cloning and expressing T cell engagement molecules and components thereof include those described in Bianchi and McGrew, 2003, Biotech. Biotechnol. Bioeng. 84:439-44, which reference is hereby incorporated by reference. Other suitable expression vectors are discussed, for example, in Methods Enzymol., Vol. 185 (DV Goeddel, ed.), 1990, New York: Academic Press.

[0286] Typically, expression vectors used in any host cell to produce PSMA-targeted T cell engaging molecules will contain sequences for cloning and expressing exogenous nucleotide sequences encoding T cell engaging molecules or components thereof. In certain embodiments, such sequences (collectively referred to as "flanking sequences") will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, an entire intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting a nucleic acid encoding a polypeptide to be expressed, and a selectable marker element.

[0287] Optionally, the vector may contain a "tag" encoding sequence, i.e., an oligonucleotide molecule located at the 5' or 3' end of the PSMA-targeted T cell engaging molecule encoding sequence; the oligonucleotide sequence encodes poly-His (such as hexameric His), or another "tag" against which there is a commercially available antibody, such as The tag is typically fused to the polypeptide when it is expressed and can be used as a means of affinity purification or detection of PSMA-targeted T cell engaging molecules from host cells. Affinity purification can be achieved, for example, by column chromatography using antibodies against the tag as an affinity matrix. Optionally, the tag can then be removed from the purified T cell engaging molecule by various means, such as cleavage using certain peptidases.

[0288] Expression and cloning vectors will typically contain a promoter that is recognized by the host cell and is operably linked to a nucleic acid molecule encoding a PSMA-targeted T cell engaging molecule. As used herein, the term "operably linked" refers to the connection of two or more nucleic acid sequences in a manner that results in the production of a nucleic acid molecule capable of directing the transcription of a given gene and / or the synthesis of a desired protein molecule. For example, control sequences in a vector that are "operably linked" to a protein coding sequence are linked thereto so that the protein coding sequence is expressed under conditions compatible with the transcriptional activity of these control sequences. More specifically, a promoter and / or enhancer sequence (including any combination of cis-acting transcriptional control elements) is operably linked to a coding sequence if it stimulates or regulates the transcription of the coding sequence in an appropriate host cell or other expression system. Many promoters that are recognized by a variety of potential host cells are well known to those skilled in the art. For example, suitable promoters for use with mammalian host cells include those obtained from viral genomes such as polyoma virus, transmissible epithelioma virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). A suitable promoter is operably linked to a polynucleotide encoding, for example, a PSMA-targeted T cell engager molecule or a component thereof, by removing the promoter from the source nucleic acid via restriction enzyme digestion and inserting the desired promoter sequence into the vector.

[0289] Expression vectors for recombinant production of the PSMA-targeted T cell engaging molecules described herein can be constructed from starting vectors, such as commercially available vectors. These vectors may or may not contain all of the desired flanking sequences. In the event that one or more of the desired flanking sequences are not already present in the vector, they can be obtained independently and ligated into the vector. Methods for obtaining each flanking sequence are well known to those skilled in the art. The expression vector can be introduced into a host cell, thereby producing the PSMA-targeted T cell engaging molecules encoded by the nucleic acid present in the vector.

[0290] After the vectors have been constructed and one or more nucleic acid molecules encoding the PSMA-targeted T cell engaging molecules or components thereof have been inserted into one or more appropriate sites of the one or more vectors, the one or more complete vectors can be inserted into suitable host cells for amplification and / or polypeptide expression. As used herein, the term "host cell" refers to a cell that has been transformed or is capable of being transformed with a nucleic acid and thereby expresses a gene of interest. The term includes progeny of a parent cell, whether or not the progeny is identical to the original parent cell in morphology or genetic makeup, as long as the gene of interest is present. A host cell comprising an isolated polynucleotide or nucleic acid encoding a T cell engaging molecule, preferably operably linked to at least one expression control sequence (e.g., a promoter or enhancer), is a "recombinant host cell".

[0291] The expression vector of the polypeptide can be transformed into the selected host cell by the well-known method including the following: transfection, infection, calcium phosphate coprecipitation, electroporation, microinjection, lipofection, DEAE-dextran mediated transfection or other known technology. This method will vary in part with the type of host cell used.

[0292] When cultured under appropriate conditions, host cells synthesize T cell engager molecules, which can then be collected from the culture medium (if the host cell secretes it into the culture medium) or directly from the host cell that produced it (if it is not secreted). The selection of a suitable host cell will depend on various factors, such as the desired expression level, polypeptide modifications (such as glycosylation or phosphorylation) required or necessary for activity, and ease of folding into a biologically active molecule. Suitable host cells include, but are not limited to, prokaryotic cells (e.g., E. coli cells, B. subtilis cells), yeast cells (Saccharmoyces cerevisiae cells, Pichia pastoris cells), and mammalian cells (e.g., Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells). In some embodiments, CHO cells are preferred host cells for expressing PSMA-targeted T cell engager molecules.

[0293] The host cells are transformed or transfected with the above-mentioned expression vectors to produce the T cell engagement molecules, and cultured in a conventional nutrient medium suitably modified to induce promoters, select transformants or amplify genes encoding the desired sequence. Host cells for producing T cell engagement molecules can be cultured in a variety of culture media. Commercially available culture media suitable for culturing host cells, such as Ham's F10 (Sigma), Minimal Essential Medium (MEM, Sigma), RPMI-1640 (Sigma) and Dulbecco's Modified Eagle Medium (DMEM, Sigma). In addition, any of the media described in Ham et al., Meth. Enz. 58:44, 1979; Barnes et al., Anal. Biochem. 102:255, 1980; U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, or 5,122,469; WO 90 / 03430; or WO 87 / 00195 can be used as a culture medium for the host cells. If necessary, any of these media can be supplemented with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as gentamycin TM ) drugs), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art. The culture conditions (such as temperature, pH, etc.) are those previously used with the host cell selected for expression and will be clear to the ordinarily skilled artisan.

[0294] After culturing the host cells, the T cell engaging molecules can be produced intracellularly in the periplasmic space, or directly secreted into the culture medium. If the T cell engaging molecules are produced intracellularly, as a first step, the host cells are dissolved (e.g., by mechanical shearing, osmotic shock or enzymatic methods), and the particulate debris (e.g., host cells and dissolved fragments) are removed, for example, by centrifugation, microfiltration or ultrafiltration. If the T cell engaging molecules are secreted into the culture medium, the T cell engaging molecules can be separated from the host cells by centrifugation or microfiltration, and optionally subsequently concentrated by ultrafiltration. The PSMA-targeted T cell engaging molecules can be further purified or partially purified using, for example, one or more chromatographic steps such as affinity chromatography (e.g., protein A, protein L or protein G affinity chromatography), cation exchange chromatography, anion exchange chromatography, hydroxyapatite chromatography, hydrophobic interaction chromatography or hybrid chromatography.

[0295] The PSMA-targeted T cell engaging molecules and anti-androgen compounds are generally administered to a patient in a pharmaceutical composition, which may include a pharmaceutically acceptable carrier, excipient or diluent. "Pharmaceutically acceptable" refers to molecules, compounds and compositions that are non-toxic to human recipients at the dosages and concentrations employed and / or do not produce allergic or adverse reactions when administered to humans. In certain embodiments, the pharmaceutical composition may contain formulation materials to adjust, maintain or preserve, for example, the pH, osmotic properties, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, absorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (such as ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (such as borates, bicarbonates, Tris-HCl, citrates, phosphates, or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediaminetetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, β-cyclodextrin, or hydroxypropyl-β-cyclodextrin); fillers; coatings, monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose, or dextrin); proteins (such as serum albumin, gelatin, or immunoglobulins); colorants, flavorings, and diluents; emulsifiers; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium , potassium, magnesium, calcium, acetate, hydrochloride, phosphate, etc.); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenylethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerol, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, Sorbitan esters, polysorbates (e.g., polysorbate 20, polysorbate 80), triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancers (e.g., sucrose or sorbitol); tonicity enhancers (e.g., alkali metal halides, preferably sodium chloride or potassium chloride, mannitol, sorbitol); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants. Methods and suitable materials for formulating molecules for therapeutic use are known in the pharmaceutical art and are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th edition, (AR Genrmo ed.), 1990, Mack Publishing Company.Pharmaceutical compositions comprising a PSMA-targeted T cell engaging molecule or an anti-androgen compound to be administered according to the methods of the present invention include, but are not limited to, solid, liquid, frozen, and lyophilized compositions.

[0296] If the pharmaceutical composition has been lyophilized, the lyophilized material is reconstituted in an appropriate liquid prior to administration. The lyophilized material can be reconstituted in, for example, bacteriostatic water for injection (BWFI), normal saline, phosphate buffered saline (PBS), or the same formulation in which the protein was prior to freeze drying.

[0297] In some embodiments, the choice of carriers and excipients incorporated into the pharmaceutical composition affects the physical state, stability, in vivo release rate, and in vivo clearance rate of the T cell engaging molecule or anti-androgen compound. In certain embodiments, the primary vehicle or carrier in the pharmaceutical composition may be aqueous or non-aqueous. For example, a suitable vehicle or carrier for the T cell engaging molecule may be water for injection, physiological saline solution, possibly supplemented with other materials or excipients commonly found in compositions for parenteral administration.

[0298] In certain embodiments, the pharmaceutical composition comprises an effective amount of a PSMA-targeted T cell engaging molecule or an anti-androgen compound and one or more excipients. The effective amount can be a therapeutic dose, or it can be a smaller amount, such as a priming dose or a unit dose. Excipients can serve a variety of purposes, such as adjusting the physical, chemical, or biological properties of the formulation, such as adjusting viscosity and / or stabilizing such formulations to prevent degradation and corruption, for example, due to stresses that occur during manufacture, transportation, storage, preparation prior to use, and administration.

[0299] In some embodiments, a pharmaceutical composition comprising an effective amount of a PSMA-targeted T cell engaging molecule to be administered to a patient according to the methods of the present invention comprises a buffer. A buffer is used to maintain the composition at physiological pH or slightly lower pH, typically in the pH range of about 4.0 to about 6.5. Suitable buffers include, but are not limited to, glutamate, aspartate, acetate, Tris, citrate, histidine, succinate, and phosphate buffers. In certain embodiments, a pharmaceutical composition administered according to the methods described herein comprises a glutamate buffer, particularly an L-glutamate buffer. A pharmaceutical composition comprising a glutamate buffer may have a pH of about 4.0 to about 5.5, a pH of about 4.0 to about 4.4, or a pH of about 4.2 to about 4.8.

[0300] The pharmaceutical composition comprising an effective amount of PSMA-targeted T cell engaging molecules may further include a surfactant. As used herein, the term "surfactant" refers to a substance for reducing the surface tension of a liquid dissolved therein. For a variety of purposes (including, for example, preventing or controlling aggregation, particle formation and / or surface adsorption in a liquid formulation, or preventing or controlling these phenomena during the freeze-drying and / or reconstitution process of a freeze-dried formulation), a surfactant may be included in the pharmaceutical composition. Surfactants include, for example, amphiphilic organic compounds that exhibit partial solubility in both organic solvents and aqueous solutions. The general characteristics of surfactants include their ability to reduce the surface tension of water, reduce the interfacial tension between oil and water, and form micelles. The surfactants that can be incorporated into the pharmaceutical composition used in the method of the present invention include both nonionic surfactants and ionic surfactants. Suitable nonionic surfactants include, but are not limited to, alkyl poly (ethylene oxide), alkyl polyglucosides (such as octyl glucoside and decyl maltoside), fatty alcohols (such as cetyl alcohol and oleyl alcohol), cocamide MEA, cocamide DEA, and cocamide TEA. Specific examples of nonionic surfactants include polysorbates, including, for example, polysorbate 20, polysorbate 28, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85, etc.; Poloxamers, including, for example, poloxamer 188 (also known as poloxalkol or poly(ethylene oxide)-poly(propylene oxide)), poloxamer 407 or polyethylene-polypropylene glycol, etc.; and polyethylene glycol (PEG). Suitable ionic surfactants include, for example, anionic, cationic and zwitterionic surfactants. Anionic surfactants include, but are not limited to, sulfonate-based or carboxylate-based surfactants, such as soaps, soaps, sodium dodecyl sulfate (SDS), ammonium lauryl sulfate and other alkyl sulfates. Cationic surfactants include, but are not limited to, quaternary ammonium-based surfactants such as cetyl trimethyl ammonium bromide (CTAB), other alkyl trimethyl ammonium salts, cetyl pyridinium chloride, polyethoxylated tallow amine (POEA) and benzalkonium chloride. Zwitterionic or amphoteric surfactants include, for example, dodecyl betaine, dodecyl dimethyl amine oxide, cocamidopropyl betaine and coconut oil amphoteric glycinate. In certain embodiments, the pharmaceutical composition administered according to the methods described herein comprises a nonionic surfactant. In one embodiment, the nonionic surfactant is polysorbate 20. In another embodiment, the nonionic surfactant is polysorbate 80.

[0301] In certain embodiments, the pharmaceutical composition comprising an effective amount of a PSMA-targeted T cell engaging molecule further comprises a stabilizer. As used herein, the term "stabilizer" refers to an excipient that stabilizes the native conformation of a polypeptide or T cell engaging molecule and / or prevents or reduces the physical or chemical degradation of a polypeptide or T cell engaging molecule. Suitable stabilizers include, but are not limited to, polyols (e.g., sorbitol, glycerol, mannitol, xylitol, maltitol, lactitol, erythritol, and threitol), sugars (e.g., fructose, glucose, glyceraldehyde, lactose, arabinose, mannose, xylose, ribose, rhamnose, galactose, maltose, sucrose, trehalose, sorbose, sucralose, melezitose, and raffinose) and amino acids (e.g., glycine, methionine, proline, lysine, arginine, histidine, or glutamic acid). In some embodiments, the pharmaceutical composition comprises a sugar as a stabilizer. In these and other embodiments, the sugar is sucrose.

[0302] Exemplary pharmaceutical compositions comprising T cell engaging molecules, including PSMA-targeted T cell engaging molecules, are described in WO 2018 / 141910, which is hereby incorporated by reference in its entirety. In certain embodiments, a pharmaceutical composition useful for treating prostate cancer according to the methods described herein comprises about 0.5 mg / ml to about 2 mg / ml of a PSMA-targeted T cell engaging molecule, about 5 mM to about 20 mM of L-glutamic acid, about 0.005% to about 0.015% weight / volume (w / v) of a polysorbate (e.g., polysorbate 20 or polysorbate 80), and about 7% to about 12% (w / v) of sucrose. In other embodiments, the pharmaceutical composition comprises about 0.5 mg / ml to about 1 mg / ml of a PSMA-targeted T cell engaging molecule, about 8 mM to about 12 mM L-glutamic acid, about 0.008% to about 0.012% (w / v) of a polysorbate (e.g., polysorbate 20 or polysorbate 80), and about 8% to about 10% (w / v) of sucrose. The pH of these compositions is in the range of about 4.0 to about 4.4 (e.g., the pH is about 4.0, about 4.1, about 4.2, about 4.3, or about 4.4).

[0303] Any pharmaceutical composition comprising a PSMA-targeted T cell engaging molecule described herein can be lyophilized and reconstituted with, for example, sterile water for injection prior to administration to a patient. The reconstitution volume will depend on the protein content after lyophilization and the desired concentration of the T cell engaging molecule in the reconstituted solution, but can be from about 0.5 ml to about 5 ml. The reconstituted solution can be further diluted with a diluent (e.g., saline and / or an intravenous solution stabilizer (IVSS)) as appropriate prior to administration to a patient, so as to administer the doses described herein according to the methods of the invention.

[0304] Any of the PSMA-targeted T cell engaging molecules described herein (including the single-chain polypeptides described in Table 6) can be incorporated into any of the pharmaceutical compositions described above and administered to a patient according to the methods described herein. In a preferred embodiment, the PSMA-targeted T cell engaging molecule comprises the amino acid sequence of SEQ ID NO: 140 (eg, icapatumumab). In another preferred embodiment, the PSMA-targeted T cell engaging molecule comprises the amino acid sequence of SEQ ID NO: 141.

[0305] The anti-androgen compounds administered according to the methods of the invention will typically be formulated in the form of an oral dosage form. Oral dosage forms include, but are not limited to, tablets, pills, pellets, capsules, powders, lozenges, granules, solutions, suspensions, emulsions, syrups, elixirs, and sprays. Some oral dosage forms (such as tablets or capsules) may contain an enteric coating or film.

[0306] The following examples, including experiments performed and results achieved, are provided for illustrative purposes only and should not be construed as limiting the scope of the appended claims.

[0307] Examples

[0308] Example 1. Phase 1b Study Evaluating AMG160 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

[0309] AMG 160 (also known as icapatumumab) is a half-life extended (HLE) (Bispecific T cell engager) molecule, which binds both human PSMA and human CD3 and includes a single-chain IgG Fc domain. The amino acid sequence of AMG 160 is shown in SEQ ID NO: 140. AMG 160 is designed to involve the patient's T cells in killing prostate cancer cells via the combination of CD3 on T cells and PSMA on cancer cells. Enzalutamide is an androgen receptor inhibitor, suitable for treating patients with castration-resistant prostate cancer (and in some areas, metastatic hormone-sensitive prostate cancer). However, patients receiving enzalutamide may experience disease progression or recurrence, which is partly due to mutations in androgen receptors (such as AR-V7) and increased androgen receptor expression and other mechanisms (Galletti et al., Cancer Treat Rev. [Cancer Treatment Review], Vol. 57: 16-27, 2017). Since these resistance mechanisms do not necessarily confer resistance to immunotherapy (such as AMG 160), the combination therapy of AMG 160 and enzalutamide may provide better efficacy. In addition, it is reported that enzalutamide rapidly upregulates the expression of PSMA in prostate cancer cells and enhances AMG 160-mediated cytotoxicity of prostate cancer cells in vitro (see, e.g., Deegen et al., Clin. Cancer Res. [Clinical Cancer Research], Vol. 27: 2928-2937, 2021; Aggarwal et al., Eur. Urol. Oncol. [European Journal of Urological Oncology], Vol. 1: 78-82, 2018; Emmett et al., J Nucl. Med. [Journal of Nuclear Medicine], Vol. 60: 950-954, 2019). The purpose of the study is to evaluate the safety, tolerability and preliminary efficacy of AMG 160 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).

[0310] After signing the informed consent, patients entered a screening period (up to 28 days) during which they were assessed for eligibility. Eligible patients had mCRPC with histologically or cytologically confirmed prostate adenocarcinoma without pure neuroendocrine differentiation or small cell features. Patients who planned to receive enzalutamide for the first time in the metastatic setting were eligible to participate in the study. Specifically, patients were recruited into the study if they met all of the following key inclusion criteria:

[0311] Histologically or cytologically confirmed mCRPC without pure neuroendocrine differentiation or small cell features;

[0312] · Have undergone bilateral orchiectomy or are receiving continuous androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists or antagonists;

[0313] Total serum testosterone level ≤ 50 ng / dL or 1.7 nmol / L; and

[0314] Planned to receive enzalutamide for the first time in mCRPC

[0315] Patients were excluded from the study if they: (i) had a confirmed history of or current autoimmune disease or other disease requiring permanent immunosuppressive therapy; (ii) had previously received enzalutamide; (iii) had CNS metastases or leptomeningeal disease; (iv) had previously been treated with a taxane for mCRPC; (v) had undergone major surgery and / or radiation therapy within 4 weeks; (vi) had used a strong CYP2C8 inhibitor (e.g., gemfibrozil) within 7 days before the first dose of AMG 160 or a strong CYP3A4 inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort) within 28 days before the first dose of AMG 160; or (vii) had received a 4-week course of chemotherapy or chemotherapy prior to the first dose of AMG 160. 160 Prior use of narrow therapeutic index drugs that are substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin), or CYP2C19 (e.g., S-mephenytoin, clopidogrel).

[0316] In the first patient cohort (cohort 1), in cycle 1, AMG 160 was administered at a dose of 0.09 mg by continuous intravenous infusion (also referred to as extended IV (eIV) infusion) over the course of 72 hours on days 1 to 3 of a 28-day cycle, followed by a 0.3 mg therapeutic dose (see Table 8 below) by short IV infusion (sIV; about 60 minutes) on days 8 and 22 of a 28-day cycle. The initial 0.09 mg dose was administered at a constant rate over a 3-day continuous infusion period, so that the total dose was delivered at a rate of 0.03 mg / day for 3 days. There was a 7-day infusion-free period between cycle 1 and cycle 2 to maintain a 14-day dosing interval between the infusion on day 22 of cycle 1 and the infusion on day 1 of cycle 2. In cycle 2 and all other subsequent cycles, AMG 160 was administered at a dose of 0.3 mg by short IV infusion (about 60 min) once every two weeks (Q2W) in a 28-day cycle on days 1 and 15. The day of the first dose of AMG 160 was defined as Day 1 of each of the 28-day cycles. In Cohort 1, enzalutamide was administered orally (PO) once daily (QD) at a dose of 160 mg starting on Cycle 1 Day 1 (i.e., the first day of treatment with AMG 160) or up to 3 days after Cycle 1 Day 1.

[0317] In Cycle 1, all patients were pretreated with 8 mg PO dexamethasone (or an equivalent dose of other corticosteroids) 6-16 hours before all doses of AMG 160. In addition, in Cycle 1, dexamethasone 8 mg IV (or an equivalent dose of other corticosteroids) was administered within 1 hour before all doses of AMG 160. If a subject experienced Grade 2 or higher cytokine release syndrome (CRS) in Cycle 1, 8 mg dexamethasone IV premedication was administered on Day 1 of Cycle 2. Otherwise, if tolerated, dexamethasone premedication was reduced in Cycle 2 (e.g., 4-8 mg dexamethasone on Day 1 of Cycle 2 and 0-4 mg on Day 15 of Cycle 2). Corticosteroid eye drops (e.g., 1% prednisolone acetate, 2 drops per eye, 4 times a day) were administered with AMG 160 infusions: (1) within 6 hours before the start of the infusion, (2) throughout the infusion period, and (3) within 48 hours after the end of the infusion in cycles 1 and 2. Eye drop prophylaxis was at the discretion of the investigator during cycle 3 and beyond. Patients received cycles of AMG 160 in combination with enzalutamide until disease progression or unacceptable toxicity.

[0318] The antitumor activity of AMG 160 in combination with enzalutamide was evaluated by multiple measures, including objective response according to RECIST 1.1 criteria (assessed by CT or MRI scans), prostate-specific antigen (PSA) response, circulating tumor cell (CTC) response, as measured by 68 gallium( 68 Ga)-PSMA-11(or pifluxstat F-18( 18 F-DCFPyL)) positron emission tomography (PET) / computed tomography (CT) and 18 Radiographic response, progression-free survival (radiographic and PSA), and overall survival measured by F-fluorodeoxyglucose (FDG) PET / CT scans. CT / magnetic resonance imaging (MRI) scans were performed at baseline and every 8 weeks for the first 6 months of treatment, and then every 12 weeks thereafter. Tumor burden assessment was performed based on RECIST 1.1. To confirm progressive disease (PD), a second MRI / CT scan was performed at least 4 weeks after the first detection of radiographic progression. Responses (partial responses (PR) and complete responses (CR)) were confirmed by repeated serial assessments at least 4 weeks after the first detection of radiographic response.

[0319] PSA30 / 50 / 70 / 90 responses were defined as 30%, 50%, 70% and 90% reductions in serum PSA levels, respectively, in at least two post-treatment measurements performed at least 3 weeks apart. CTC responses were defined as CTC0 (CTC reduction >0 to 0) or CTC conversion (≥5 CTC / 7.5 mL blood to ≤4 CTC / 7.5 mL blood) measured in whole blood. 68 Ga-PSMA-11 or pifluxstat F-18 ( 18 F-DCFPyL) PET / CT scans were performed to assess PSMA-positive tumor burden and once at 12 and 24 weeks after the start of treatment to assess response. To identify PSMA-negative disease burden, a 18 F-FDG PET / CT scan.

[0320] Adverse events were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, available at ctep.cancer.gov / protocolDevelopment / electronic_applications / ctc.htm, but CRS was graded according to the criteria described in Lee et al., Blood, Vol. 124: 188-195, 2014. Tumor lysis syndrome was graded according to the Cairo Bishop criteria mentioned in Coiffier et al., J. Clin. Oncol., Vol. 26: 2767-2778, 2008, and immune effector cell-associated neurological syndrome (ICANS) was assessed using the criteria described in Lee et al., Biol. Blood Marrow Transplant., Vol. 25: 625-638, 2019.

[0321] Four patients were recruited into cohort 1, and at the time of data analysis, all four patients were continuing treatment. Three of the four patients were eligible for dose-limiting toxicity (DLT) evaluation. Of these three patients, two had DLT (grade 3 CRS and grade 3 anemia requiring transfusion). Both DLTs occurred during the combination therapy (ie, after the patient received both AMG 160 and enzalutamide). All four subjects had grade 2 CRS, which was associated with the first or second dose of AMG 160. There were 10 serious adverse events associated with AMG 160 research products. All four patients showed PSA90 responses, all of which were confirmed responses. According to radiographic scans during treatment, all four patients were assessed as stable. None of the four patients could be evaluated by RECIST because none of them had target lesions that could be measured according to RECIST 1.1 standards. Patients who cannot be evaluated by RECIST may only be assessed as having a complete response (CR), stable disease (SD), or progressive disease (PD).

[0322] Preliminary results from cohort 1 showed that the combination of enzalutamide and AMG 160 at this dose level produced significant efficacy in all evaluable patients with PSA90 responses and positive radiographic responses (stable disease). However, at this dose level, the combination of enzalutamide treatment started simultaneously with AMG 160 resulted in DLT in most patients. These results were somewhat unexpected because the overlap in toxicity between the two drugs was unexpected, given the differences in their biological mechanisms and reported safety risks. Two new cohorts (cohort 2a and cohort 2b) were opened up, in which the treatment dose of AMG160 was reduced from 0.3 mg to 0.15 mg (see Table 8 below). In addition, in cohort 2b, the start of enzalutamide treatment was delayed to day 15 of cycle 1. The specific dosing regimens for AMG 160 and enzalutamide in cohorts 2a and 2b are as follows:

[0323] Queue 2a

[0324] o In Cycle 1, 0.09 mg of AMG 160 was administered by eIV infusion over the course of 72 hours on Days 1 to 3 of a 28-day cycle, followed by a 0.15 mg therapeutic dose administered as a short IV infusion (sIV; approximately 60 minutes) on Days 8 and 22 of a 28-day cycle. For Cycle 2 and all other subsequent cycles, AMG 160 was administered by sIV at a dose of 0.15 mg once every two weeks in a 28-day cycle, on Days 1 and 15. There was a 7-day infusion-free period between Cycles 1 and 2.

[0325] o Administer 160 mg of enzalutamide orally once daily starting on Cycle 1 Day 1 or up to 3 days after Cycle 1 Day 1.

[0326] Cohort 2b

[0327] o In Cycle 1, 0.09 mg of AMG 160 was administered by eIV infusion over the course of 72 hours on Days 1 to 3 of a 28-day cycle, followed by a 0.15 mg therapeutic dose administered by sIV infusion on Days 8 and 22 of a 28-day cycle. For Cycle 2 and all other subsequent cycles, AMG 160 was administered by sIV at a dose of 0.15 mg once every two weeks in a 28-day cycle, on Days 1 and 15. There was a 7-day infusion-free period between Cycles 1 and 2.

[0328] o Beginning on Cycle 1 Day 15, administer 160 mg of enzalutamide orally once daily.

[0329] Three patients were enrolled in each of cohorts 2a and 2b. As of the date of data analysis, 2 of 3 patients continued treatment in cohort 2a, and 1 patient discontinued treatment due to adverse events (grade 3 CRS and grade 3 myocardial infarction). Two of the three patients in cohort 2b continued treatment, while 1 patient discontinued treatment due to progressive disease. In cohort 2a, where enzalutamide treatment was started on day 1 of cycle 1 (i.e., at the same time as AMG 160), all three patients were evaluable for DLT, and of these three patients, one patient developed a DLT (grade 3 hearing loss) during the combination treatment period. One patient developed grade 3 CRS, while the worst CRS grade in the other two patients was grade 2. There were 3 serious adverse events related to the AMG 160 investigational product. All three patients had a decrease in PSA levels, with 1 PSA90 response (confirmed), 1 PSA50 response (confirmed), and 1 PSA30 response (unconfirmed). At the time of data analysis, two of the three patients had on-treatment radiographic scans, and one of these two patients was RECIST-evaluable (i.e., had measurable target lesions at baseline). Of these two patients, one had a confirmed partial response and one had stable disease. Two of the three patients enrolled in Cohort 2a had previously been treated with another anti-androgen therapy: one patient had previously received abiraterone, and the other had previously received abiraterone and darolutamide.

[0330] In cohort 2b, where the start of enzalutamide treatment was delayed until day 15 of cycle 1 (i.e., after the patients had received the first two doses of AMG160 (including the first treatment dose of AMG 160 on day 8 of cycle 1)), all three patients were evaluable for DLT, but no DLT was observed. Two of the patients had grade 2 CRS, and one patient had a grade 1 CRS grade. There were no serious adverse events. In terms of anti-tumor efficacy, two patients had a confirmed PSA90 response and one patient did not show a PSA response. Only one patient who was unable to undergo RECIST evaluation (i.e., had no measurable target lesions) had an on-treatment scan at the time of data analysis, and his disease was stable. One of the three patients in cohort 2b had previously been treated with anti-androgen therapy (apalutamide).

[0331] Results from cohorts 2a and 2b showed that delaying the start of enzalutamide treatment to the second week of cycle 1 (e.g., about 7 days after administering the first therapeutic dose of AMG 160) significantly improved the safety profile of the combination therapy, because no patient in cohort 2b experienced DLT or serious adverse events. When the start of enzalutamide treatment was delayed, the severity of CRS associated with the administration of AMG 160 was also reduced. The anti-tumor efficacy between cohorts 2a and 2b was comparable, with two-thirds of patients in both cohorts showing at least a PSA50 response. In view of these results, four patients were recruited to cohort 1a, in which the treatment dose of AMG 160 was increased to 0.3 mg and enzalutamide treatment began on day 15 of cycle 1 (see Table 8 below). Preliminary results from a patient in cohort 1a who received previous abiraterone treatment showed that this dosing regimen produced a PSA90 (unconfirmed) response. It is expected that the anti-tumor efficacy of the combination according to this dosing regimen will be similar in the other two enrolled patients and that the tolerability profile will be significantly improved compared to that observed in Cohort 1, where few or no DLTs or serious adverse events were observed.

[0332] Table 8. Summary of dosing regimens for the first cycle of AMG 160 and enzalutamide combination therapy

[0333]

[0334] 1 Measured from Day 1 (D1), which is the first day that patients receive their first dose of AMG 160 eIV = extended IV infusion sIV = short IV infusion (approximately 60 minutes)

[0335] 2 Enzalutamide dosing began on Cycle 1 Day 1 (C1D1) or up to 3 days after Cycle 1 Day 1 and continued QD on every day of the cycle.

[0336] 3 Enzalutamide dosing began on cycle 1 day 15 (C1D15) and continued QD every day of the cycle.

[0337] A second interim analysis was performed on the data from cohorts 1, 1a, 2a, and 2b. A summary of the results from this second interim analysis is provided in Table 9 below. The results from this second interim analysis are consistent with the results from the above-mentioned preliminary interim analysis. Specifically, when the initial dose of enzalutamide was delayed until after the first administration of a therapeutic dose of AMG 160 (cohorts 1a and 2b), patients had fewer serious adverse events, DLTs, and CRS events compared to starting enzalutamide on the same day as the initial dose of AMG 160. When AMG 160 was administered at a therapeutic dose of 0.15 mg (cohorts 2a and 2b), PSA responses were comparable between cohorts, indicating that delaying the start time of enzalutamide treatment did not affect the anti-tumor efficacy of the combination therapy. At the 0.3 mg therapeutic dose level of AMG 160, only 2 of the 4 patients in cohort 1a had a PSA90 response, compared to 4 patients in cohort 1 who all had a PSA90 response when starting enzalutamide on day 1. However, all patients in cohort 1a had been previously treated with at least one novel hormone therapy (NHT), whereas 3 of the 4 patients in cohort 1 had not received NHT. This could explain the lower PSA response rate in cohort 1a. At the time of data analysis, only 2 of the 14 patients in all four cohorts were available for RECIST 1.1 evaluation. Interestingly, the only objective RECIST response was observed in cohort 1a, in which AMG 160 was administered at a therapeutic dose of 0.3 mg and the initial dose of enzalutamide was delayed until day 15 of cycle 1.

[0338] Overall, the results of this study show that delaying the initial dose of enzalutamide relative to the administration of the first therapeutic dose of AMG 160 improves the tolerability of the combination therapy, allowing for the administration of higher therapeutic doses of AMG 160 to maximize the antitumor efficacy of the combination.

[0339] Table 9. Summary of interim results of AMG 160 and enzalutamide combination therapy in mCRPC

[0340]

[0341] a Upon review, this event (grade 1 fever outside the DLT period) did not qualify as a DLT, and the true number of subjects who experienced a DLT in this cohort was 0.

[0342] bCRS grade 3 event on C1D8 before starting enzalutamide (ie, outside the combination therapy window)

[0343] c Subject incidence of each indicated event

[0344] TEAE = treatment-emergent adverse event; SAE = serious adverse event; ORR = objective response rate

[0345] Example 2. Phase 1b study evaluating AMG160 in combination with abiraterone in patients with metastatic castration-resistant prostate cancer

[0346] Abiraterone is a cytochrome P450 (CYP) 17 inhibitor, which is combined with prednisone (or prednisolone in some regions) for the treatment of patients with mCRPC (and in some regions metastatic or high-risk castration-sensitive prostate cancer). Like enzalutamide and other NHTs, it is reported that abiraterone upregulates the expression of PSMA (the target of AMG 160 bispecific T cell engagers) on prostate cancer cells (Aggarwal et al., Eur. Urol. Oncol. [European Journal of Urological Oncology], Vol. 1: 78-82, 2018; Emmett et al., J Nucl. Med. [Journal of Nuclear Medicine], Vol. 60: 950-954, 2019). Therefore, the combination therapy of AMG 160 (a PSMA x CD3 T cell engager) and abiraterone can provide synergistic anti-tumor efficacy. The main purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of AMG 160 combined with abiraterone in patients with mCRPC.

[0347] After signing the informed consent, patients entered a screening period (up to 28 days) during which patients were assessed for eligibility. Eligible patients had mCRPC with histologically or cytologically confirmed prostate adenocarcinoma without pure neuroendocrine differentiation or small cell features. Patients who planned to receive abiraterone for the first time in the metastatic setting were eligible to participate in the study. Specifically, patients were recruited into the study if they met all of the following key inclusion criteria:

[0348] Histologically or cytologically confirmed mCRPC without pure neuroendocrine differentiation or small cell features;

[0349] · Have undergone bilateral orchiectomy or are receiving continuous androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists or antagonists;

[0350] Total serum testosterone level ≤ 50 ng / dL or 1.7 nmol / L; and

[0351] Planned first-time recipient of abiraterone for mCRPC

[0352] Patients were excluded from the study if they: (i) had a history of or current autoimmune disease or other disease requiring permanent immunosuppressive therapy; (ii) had previously received abiraterone; (iii) had CNS metastases or leptomeningeal disease; (iv) had previously been treated with a taxane for mCRPC; (v) had undergone major surgery and / or radiation therapy within 4 weeks; (vi) had moderate or severe hepatic impairment (Class B and C Child-Pugh) at baseline; (vii) had uncontrolled hypertension, hypokalemia, or fluid retention; (viii) had a history of or current adrenal insufficiency; (ix) had used a strong CYP3A4 inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort) within 28 days prior to the first dose of AMG 160; or (x) had received a CYP3A4 inhibitor (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort) within 28 days prior to the first dose of AMG 160. 160 Use of concomitant medications that are sensitive substrates of CYP2D6 (e.g., thioridazine) within the previous 7 days.

[0353] AMG 160 (amino acid sequence shown in SEQ ID NO: 140) was administered as described in Example 1, wherein the first dose of the first cycle was administered as a 72-hour extended IV infusion on days 1 to 3, followed by a therapeutic dose by short IV infusion (sIV; about 60 minutes) on days 8 and 22 of the first cycle. After a 7-day infusion-free period between the first and second cycles, AMG 160 was administered Q2W by short IV infusion on days 1 and 15 of the second cycle and all other subsequent cycles. Starting from day 15±3 of the first cycle, abiraterone was orally administered once a day at a dose of 1,000 mg. The day of the first dose of AMG 160 was defined as day 1 of each of the 28-day cycles. On the same day that the patient received abiraterone, a 5 mg dose of prednisone was orally administered twice a day (BID). In some regions, prednisone was replaced with a 10 mg dose of prednisolone once a day. Table 10 below summarizes the dosing regimen for the two patient cohorts in cycle 1.

[0354] Table 10. Summary of dosing regimens for the first cycle of AMG 160 and abiraterone combination therapy

[0355]

[0356] 1 Measured from Day 1 (D1), which is the first day that patients receive their first dose of AMG 160 eIV = extended IV infusion sIV = short IV infusion (approximately 60 minutes)

[0357] 2 Abiraterone dosing began on cycle 1 day 15 (C1D15) ± 3 days (i.e., between C1D12 and C1D18) and continued QD on every day of the cycle.

[0358] In Cycle 1, all patients were pretreated with 8 mg PO dexamethasone (or an equivalent dose of other corticosteroids) 6-16 hours before all doses of AMG 160. In addition, in Cycle 1, dexamethasone 8 mg IV (or an equivalent dose of other corticosteroids) was administered within 1 hour before all doses of AMG 160. If a subject experienced Grade 2 or higher CRS in Cycle 1, 8 mg dexamethasone IV premedication was administered on Day 1 of Cycle 2. Otherwise, if tolerated, dexamethasone premedication was reduced in Cycle 2 (e.g., 4-8 mg dexamethasone on Day 1 of Cycle 2 and 0-4 mg on Day 15 of Cycle 2). Corticosteroid eye drops (e.g., 1% prednisolone acetate, 2 drops per eye, 4 times a day) were used with AMG 160 infusions: (1) within 6 hours before the start of the infusion, (2) throughout the infusion period, and (3) within 48 hours after the end of the infusion in cycles 1 and 2. Eye drop prophylaxis was at the discretion of the investigator during cycle 3 and beyond. Patients received cycles of treatment with AMG 160 in combination with abiraterone until disease progression or unacceptable toxicity. Adverse events and antitumor efficacy were assessed as described in Example 1.

[0359] Four patients were enrolled in Cohort 1, and three patients were initially enrolled in Cohort 2. At the time of data analysis, all four patients in Cohort 1 continued treatment, and two of the three patients in Cohort 2 continued treatment, with one patient discontinuing due to radiographic disease progression. All four patients in Cohort 1 were evaluable for DLT, but no DLT was observed. Two patients each experienced one serious adverse event, but neither event was related to the AMG 160 investigational product. Two of the four patients experienced grade 2 CRS, and the worst CRS grade in the other two patients was grade 1. No hepatotoxicity was observed. In terms of preliminary antitumor efficacy, all four patients in Cohort 1 had post-baseline PSA measurements, and one patient had a PSA90 response (confirmed), one patient had a PSA70 response (confirmed), and one patient had a PSA30 response (confirmed). Two of the four patients (one of whom had a RECIST-measurable target lesion) had an on-treatment scan at the time of data analysis, one patient showed a confirmed partial response, and the other patient had stable disease.

[0360] In cohort 2, two of the three patients were evaluable for DLT, one of whom had a DLT (grade 3 rash) on day 9 of cycle 1 before receiving abiraterone. Therefore, no DLT occurred during the combination therapy. There were six adverse events related to the AMG 160 research product, but no hepatotoxicity was observed. Two patients had grade 2 CRS, and the most severe CRS grade of one patient was grade 1. Of the three patients in cohort 2, one patient had a PSA70 response (confirmed) and one patient had a PSA30 response (confirmed). All three patients in cohort 2 had previously been treated with enzalutamide. One patient had also received previous darolutamide treatment. All three patients in cohort 2 did not have target lesions that could be measured according to RECIST (ie, RECIST evaluation could not be performed). The results of the in-treatment scans of these patients showed that two patients had stable disease and another patient had unconfirmed progressive disease. Three additional patients were recruited to cohort 2 to further study the combination therapy at this dose level.

[0361] Three other patients were recruited into queue 2, and four patients were recruited into the expansion queue receiving the same dosing regimen as those in queue 2 (table 10).A second interim analysis was performed, and a summary of the results from this analysis is provided in Table 11 below.In 10 patients recruited in queue 2 and expansion queue, only two patients had DLT, only one patient discontinued AMG 160 therapy due to adverse events occurring in treatment, and only one patient had grade 3 CRS events, which occurred on the 15th day of the 2nd cycle.In 10 patients recruited in queue 2 and expansion queue, four patients had at least PSA50 responses, and 2 of them had PSA90 responses.Only 2 of 10 patients did not receive the previous therapy (i.e., did not receive NHT) of NHT.Only 2 patients recruited in queue 2 and expansion queue can be evaluated by RECIST 1.1 (i.e., with baseline disease that can be measured according to RECIST 1.1 standards), one of whom had a partial response and another patient had stable condition.

[0362] The results of this study showed that when abiraterone treatment was initiated approximately two weeks after the start of AMG 160 treatment (and approximately 7 days after administration of the first therapeutic dose of AMG 160), the combination of AMG 160 and abiraterone was tolerable and resulted in a reduction in PSA serum levels in the majority of patients, with an objective response rate of 50%.

[0363] Table 11. Summary of interim results of AMG 160 and abiraterone combination therapy in mCRPC

[0364]

[0365] a Subject incidence of each indicated event

[0366] b Five of the six subjects in Cohort 2 were evaluable for DLT. One DLT event (grade 3 rash) occurred on C1D9 before receiving abiraterone (i.e., outside the combination therapy window)

[0367] All publications, patents and patent applications discussed and cited herein are hereby incorporated by reference in their entirety. It should be understood that the disclosed invention is not limited to the specific methods, protocols and materials described, as these may vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments and is not intended to limit the scope of the appended claims.

[0368] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

1. A method for treating prostate cancer in a patient in need thereof, the method comprising administering to the patient one or more cycles of an anti-androgen compound in combination with a T cell engaging molecule that specifically binds to human prostate specific membrane antigen (PSMA) and human CD3, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engaging molecule.

2. The method of claim 1, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 4 days to about 10 days after administering the first therapeutic dose of the T cell engaging molecule.

3. The method of claim 1 or 2, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 5 days after administering the first therapeutic dose of the T cell engaging molecule.

4. The method of claim 1 or 2, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 7 days after administering the first therapeutic dose of the T cell engaging molecule.

5. The method of any one of claims 1 to 4, wherein the T cell engaging molecule is administered by intravenous infusion.

6. The method of any one of claims 1 to 5, wherein the first cycle further comprises administering one or more priming doses of the T cell engager molecule prior to administering the first therapeutic dose of the T cell engager molecule.

7. The method of claim 6, wherein the first priming dose of the T cell engaging molecule is administered by continuous intravenous infusion over a period of 1 day to 7 days.

8. The method of claim 6 or 7, wherein the first therapeutic dose of the T cell engagement molecule is administered about 1 day to about 7 days after administration of the first priming dose of the T cell engagement molecule.

9. The method of claim 8, wherein the first therapeutic dose of the T cell engagement molecule is administered about 5 days after the first priming dose of the T cell engagement molecule is administered.

10. The method of any one of claims 1 to 9, wherein the anti-androgen compound is administered orally once daily.

11. The method of any one of claims 1 to 10, wherein the duration of the first cycle is about 28 days.

12. The method of claim 11, wherein the first cycle comprises administering a priming dose of the T cell engagement molecule by continuous intravenous infusion over days 1 to 3 of the cycle and administering a therapeutic dose of the T cell engagement molecule by intravenous push injection on days 8 and 22 of the cycle.

13. The method of claim 11, wherein the T cell engaging molecule is administered on days 1, 8, 15 and 22 of the first cycle.

14. The method of claim 11, wherein the T cell engaging molecule is administered on days 1 and 15 of the first cycle.

15. The method of any one of claims 11 to 14, wherein the anti-androgen compound is administered orally once a day on each of days 15 to 28 of the first cycle.

16. The method of any one of claims 1 to 15, wherein the anti-androgen compound is enzalutamide, abiraterone, abiraterone acetate, apalutamide, or darolutamide.

17. The method of claim 16, wherein the anti-androgen compound is enzalutamide.

18. The method of claim 17, wherein enzalutamide is administered orally at a dose of about 160 mg once daily.

19. The method of claim 16, wherein the anti-androgen compound is abiraterone or abiraterone acetate.

20. The method of claim 19, wherein abiraterone or abiraterone acetate is orally administered at a dose of about 1,000 mg once daily.

21. The method of any one of claims 1 to 20, wherein the T cell engaging molecule comprises, in order from amino to carboxyl: (i) a first domain that specifically binds to human PSMA, the first domain comprising a first immunoglobulin heavy chain variable region (VH1) and a first immunoglobulin light chain variable region (VL1); (ii) a second domain that specifically binds to human CD3, the second domain comprising a second immunoglobulin heavy chain variable region (VH2) and a second immunoglobulin light chain variable region (VL2); and (iii) An Fc domain comprising two Fc monomers, each monomer comprising an immunoglobulin hinge region, a CH2 domain and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker.

22. The method of claim 21, wherein the first domain comprises VH1 and VL1, the VH1 comprising CDRH1 having a sequence of SEQ ID NO: 14, CDRH2 having a sequence of SEQ ID NO: 16, and CDRH3 having a sequence of SEQ ID NO: 20, the VL1 comprising CDRL1 having a sequence of SEQ ID NO: 5, CDRL2 having a sequence of SEQ ID NO: 8, and CDRL3 having a sequence of SEQ ID NO: 9; and Wherein the second domain comprises VH2 and VL2, the VH2 comprises CDRH1 having the sequence of SEQ ID NO:49, CDRH2 having the sequence of SEQ ID NO:55 and CDRH3 having the sequence of SEQ ID NO:60, and the VL2 comprises CDRL1 having the sequence of SEQ ID NO:43, CDRL2 having the sequence of SEQ ID NO:44 and CDRL3 having the sequence of SEQ ID NO:

47.

23. The method of claim 22, wherein VH1 comprises the sequence of SEQ ID NO:33, VL1 comprises the sequence of SEQ ID NO:30, VH2 comprises the sequence of SEQ ID NO:72, and VL2 comprises the sequence of SEQ ID NO:

70.

24. The method of any one of claims 21 to 23, wherein the T cell engaging molecule is a single chain polypeptide comprising the sequence of SEQ ID NO:

140.

25. The method of any one of claims 21 to 24, wherein the first period is about 28 days and comprises: administering a priming dose of about 90 μg of the T cell engaging molecule by continuous intravenous infusion on days 1 to 3 of the cycle; administering a therapeutic dose of about 300 μg of the T cell engaging molecule by intravenous push on days 8 and 22 of the cycle; and The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

26. The method of any one of claims 21 to 24, wherein the first period is about 28 days and comprises: administering a priming dose of about 90 μg of the T cell engaging molecule by continuous intravenous infusion on days 1 to 3 of the cycle; administering a therapeutic dose of about 150 μg of the T cell engaging molecule by intravenous push on days 8 and 22 of the cycle; and The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

27. The method of any one of claims 1 to 26, further comprising administering to the patient a maintenance cycle of the anti-androgen compound and the T cell engaging molecule in combination, wherein the maintenance cycle comprises oral administration of the anti-androgen compound once a day on each day of the cycle and administration of a therapeutic dose of the T cell engaging molecule by intravenous push once every 7 days or once every 14 days.

28. The method of claim 27, wherein the duration of the maintenance period is about 28 days.

29. The method of claim 27 or 28, wherein the maintenance cycle is administered about 7 days after completion of the first cycle.

30. The method of any one of claims 27 to 29, wherein two or more maintenance cycles are administered to the patient.

31. The method of any one of claims 1 to 30, wherein the prostate cancer is metastatic prostate cancer.

32. The method of claim 31, wherein the prostate cancer is metastatic castration-resistant prostate cancer.

33. The method of any one of claims 1 to 32, wherein the patient has a total serum testosterone level of 50 ng / dL or less.

34. A PSMA-targeted T cell engager for use in combination with an anti-androgen compound in a method for treating prostate cancer in a patient in need thereof, wherein the method comprises administering a first cycle of the PSMA-targeted T cell engager and the anti-androgen compound, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engager molecule.

35. The PSMA-targeted T cell engaging molecule for use according to claim 34, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 4 days to about 10 days after administering the first therapeutic dose of the T cell engaging molecule.

36. The PSMA-targeted T cell engaging molecule for use according to claim 34 or 35, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 5 days after administering the first therapeutic dose of the T cell engaging molecule.

37. The PSMA-targeted T cell engaging molecule for use according to claim 34 or 35, wherein the first cycle comprises administering the first dose of the anti-androgen compound about 7 days after administering the first therapeutic dose of the T cell engaging molecule.

38. The PSMA-targeted T cell engager molecule for use according to any one of claims 34 to 37, wherein the T cell engager molecule is administered by intravenous infusion.

39. The PSMA-targeted T cell engager molecule for use according to any one of claims 34 to 38, wherein the first cycle further comprises administering one or more priming doses of the T cell engager molecule prior to administering the first therapeutic dose of the T cell engager molecule.

40. The PSMA-targeted T cell engager molecule for use according to claim 39, wherein the first priming dose of the T cell engager molecule is administered by continuous intravenous infusion over a period of 1 day to 7 days.

41. The PSMA-targeted T cell engager molecule for use according to claim 39 or 40, wherein the first therapeutic dose of the T cell engager molecule is administered about 1 day to about 7 days after the administration of the first priming dose of the T cell engager molecule.

42. The PSMA-targeted T cell engager molecule for use according to claim 41, wherein the first therapeutic dose of the T cell engager molecule is administered about 5 days after the first priming dose of the T cell engager molecule is administered.

43. The PSMA-targeted T-cell engaging molecule for use according to any one of claims 34 to 42, wherein the anti-androgen compound is administered orally once a day.

44. The PSMA-targeted T-cell engaging molecule for use according to any one of claims 34 to 43, wherein the duration of the first cycle is about 28 days.

45. The PSMA-targeted T cell engager molecule for use according to claim 44, wherein the first cycle comprises administration of a priming dose of the T cell engager molecule by continuous intravenous infusion over days 1 to 3 of the cycle, and administration of a therapeutic dose of the T cell engager molecule by intravenous push injection on days 8 and 22 of the cycle.

46. ​​The PSMA-targeted T cell engager molecule for use according to claim 44, wherein the T cell engager molecule is administered on days 1, 8, 15 and 22 of the first cycle.

47. The PSMA-targeted T cell engager molecule for use according to claim 44, wherein the T cell engager molecule is administered on days 1 and 15 of the first cycle.

48. The PSMA-targeted T-cell engaging molecule for use according to any one of claims 44 to 47, wherein the anti-androgen compound is administered orally once a day on each of days 15 to 28 of the first cycle.

49. The PSMA-targeted T-cell engager molecule for use according to any one of claims 34 to 48, wherein the anti-androgen compound is enzalutamide, abiraterone, abiraterone acetate, apalutamide or darolutamide.

50. The PSMA-targeted T cell engager molecule for use according to claim 49, wherein the anti-androgen compound is enzalutamide.

51. The PSMA-targeted T cell engager molecule for use according to claim 50, wherein enzalutamide is orally administered once daily at a dose of about 160 mg.

52. The PSMA-targeted T cell engaging molecule for use according to claim 49, wherein the anti-androgen compound is abiraterone or abiraterone acetate.

53. The PSMA-targeted T cell engaging molecule for use according to claim 52, wherein abiraterone or abiraterone acetate is orally administered at a dose of about 1,000 mg once daily.

54. The PSMA-targeted T cell engaging molecule for use according to any one of claims 34 to 53, wherein the PSMA-targeted T cell engaging molecule comprises, in order from amino to carboxyl groups: (i) a first domain that specifically binds to human PSMA, the first domain comprising a first immunoglobulin heavy chain variable region (VH1) and a first immunoglobulin light chain variable region (VL1); (ii) a second domain that specifically binds to human CD3, the second domain comprising a second immunoglobulin heavy chain variable region (VH2) and a second immunoglobulin light chain variable region (VL2); and (iii) An Fc domain comprising two Fc monomers, each monomer comprising an immunoglobulin hinge region, a CH2 domain and a CH3 domain, wherein the two Fc monomers are fused to each other via a peptide linker.

55. The PSMA-targeted T cell engaging molecule for use according to claim 54, wherein the first domain comprises VH1 and VL1, the VH1 comprising CDRH1 having the sequence of SEQ ID NO: 14, CDRH2 having the sequence of SEQ ID NO: 16, and CDRH3 having the sequence of SEQ ID NO: 20, the VL1 comprising CDRL1 having the sequence of SEQ ID NO: 5, CDRL2 having the sequence of SEQ ID NO: 8, and CDRL3 having the sequence of SEQ ID NO: 9; and Wherein the second domain comprises VH2 and VL2, the VH2 comprises CDRH1 having the sequence of SEQ ID NO:49, CDRH2 having the sequence of SEQ ID NO:55 and CDRH3 having the sequence of SEQ ID NO:60, and the VL2 comprises CDRL1 having the sequence of SEQ ID NO:43, CDRL2 having the sequence of SEQ ID NO:44 and CDRL3 having the sequence of SEQ ID NO:

47.

56. The PSMA-targeted T cell engaging molecule for use according to claim 55, wherein VH1 comprises the sequence of SEQ ID NO: 33, VL1 comprises the sequence of SEQ ID NO: 30, VH2 comprises the sequence of SEQ ID NO: 72, and VL2 comprises the sequence of SEQ ID NO:

70.

57. The PSMA-targeted T cell engaging molecule for use according to any one of claims 54 to 56, wherein the PSMA-targeted T cell engaging molecule is a single chain polypeptide comprising the sequence of SEQ ID NO:

140.

58. The PSMA-targeted T-cell engaging molecule for use according to any one of claims 54 to 57, wherein the first cycle is about 28 days and comprises: administering a priming dose of about 90 μg of the T cell engaging molecule by continuous intravenous infusion on days 1 to 3 of the cycle; administering a therapeutic dose of about 300 μg of the T cell engaging molecule by intravenous push on days 8 and 22 of the cycle; and The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

59. The PSMA-targeted T-cell engaging molecule for use according to any one of claims 54 to 57, wherein the first cycle is about 28 days and comprises: administering a priming dose of about 90 μg of the T cell engaging molecule by continuous intravenous infusion on days 1 to 3 of the cycle; administering a therapeutic dose of about 150 μg of the T cell engaging molecule by intravenous push on days 8 and 22 of the cycle; and The anti-androgen compound is administered orally once daily on each of days 15 to 28 of the cycle.

60. The PSMA-targeted T cell engager for use according to any one of claims 34 to 59, further comprising administering to the patient a maintenance cycle of the PSMA-targeted T cell engager and an anti-androgen compound, wherein the maintenance cycle comprises oral administration of the anti-androgen compound once a day on each day of the cycle and administration of a therapeutic dose of the T cell engager molecule by intravenous push once every 7 days or once every 14 days.

61. The PSMA-targeted T cell engaging molecule for use according to claim 60, wherein the duration of the maintenance period is about 28 days.

62. The PSMA-targeted T cell engaging molecule for use according to claim 60 or 61, wherein the maintenance cycle is administered about 7 days after completion of the first cycle.

63. The PSMA-targeted T cell engager molecule for use according to any one of claims 60 to 62, wherein two or more maintenance cycles are administered to the patient.

64. A PSMA-targeted T-cell engaging molecule for use according to any one of claims 34 to 63, wherein the prostate cancer is metastatic prostate cancer.

65. The PSMA-targeted T cell engaging molecule for use according to claim 64, wherein the prostate cancer is metastatic castration-resistant prostate cancer.

66. The PSMA-targeted T cell engaging molecule for use according to any one of claims 34 to 65, wherein the patient has a total serum testosterone level of 50 ng / dL or less.

67. Use of a PSMA-targeted T cell engaging molecule for the manufacture of a medicament for treating prostate cancer in a patient in need thereof, wherein the treatment comprises administering to the patient a first cycle of the PSMA-targeted T cell engaging molecule and the anti-androgen compound, wherein the first cycle comprises administering a first dose of the anti-androgen compound at least 3 days after administering a first therapeutic dose of the T cell engaging molecule.